

Wetenschappelijk overzicht IKNL 2019

Wetenschappelijk overzicht IKNL 2019

Auteur
A.M. Kuijpers-Ruurs

Inhoudsopgave

1	Algemeen	6
1.1	Publicaties met impactfactor	6
1.2	Overige publicaties	10
1.3	Proefschriften en promoties	11
1.4	Posters	11
1.5	Presentaties en abstracts	11
2	Borstkanker	13
2.1	Publicaties met impactfactor	13
2.2	Overige publicaties	17
2.3	Proefschriften en promoties	17
2.4	Boekbijdragen	17
2.5	Posters	17
2.6	Presentaties en abstracts	18
3	Bot-en wekedelentumoren	21
3.1	Publicaties met impactfactor	21
3.1	Presentaties en abstracts	21
4	Darmkanker	22
4.1	Publicaties met impactfactor	22
4.2	Overige publicaties	25
4.3	Posters	25
4.4	Presentaties en abstracts	25
5	Gynaecologische tumoren	26
5.1	Publicaties met impactfactor	26
5.2	Proefschriften en promoties	27
5.3	Posters	27
5.4	Presentaties en abstracts	27
6	Hemato-oncologie	29
6.1	Publicaties met impactfactor	29
6.2	Posters	29
6.3	Presentaties en abstracts	30
7	Hoofdhalskanker	31
7.1	Publicaties met impactfactor	31
8	Huidkanker	32
8.1	Publicaties met impactfactor	32
8.2	Proefschriften en promoties	33
9	Longkanker	34
9.1	Publicaties met impactfactor	34
9.2	Presentaties en abstracts	34
10	Neuro-endocriene tumoren	36
10.1	Publicaties met impactfactor	36
11	Neuro-oncologie	37
11.1	Publicaties met impactfactor	37
12	Upper GI & HPB	38
12.1	Publicaties met impactfactor	38
12.2	Overige publicaties	40
12.3	Proefschriften en promoties	40
12.4	Posters	40
12.5	Presentaties en abstracts	40

13	Urogenitale kanker	42
	13.1 Publicaties met impactfactor	42
	13.2 Overige publicaties	43
	13.3 Proefschriften en promoties	43
	13.4 Presentaties en abstracts	43
B1	Impactfactoren tijdschriften	44

1 Algemeen

1.1 Publicaties met impactfactor

Adam S, van de Poll-Franse LV, Mols F, Ezendam NP, de Hingh IH, Arndt V, Thong MS. The association of cancer-related fatigue with all-cause mortality of colorectal and endometrial cancer survivors: Results from the population-based PROFILES registry. *Cancer Med.* 2019 Apr 22. doi: 10.1002/cam4.2166. [Epub ahead of print]
Impactfactor: 3,357

Bernard P, Savard J, Steindorf K, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, May AM, Galvao DA, Chinapaw MJ, Stuiver MM, Griffith KA, Mesters I, Knoop H, Goedendorp MM, Bohus M, Thorsen L, Schmidt ME, Ulrich CM, Sonke GS, van Harten W, Winters-Stone KM, **Velthuis MJ**, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-de Leeuw IM, Brug J, Buffart LM. Effects and moderators of exercise on sleep in adults with cancer: Individual patient data and aggregated meta-analyses. *J Psychosom Res.* 2019 Sep;124:109746. doi: 10.1016/j.jpsychores.2019.109746. Epub 2019 Jun 23. Review.
Impactfactor: 2,722

Bottomley A, Reijneveld JC, Koller M, Flechtner H, Tomaszewski KA, Greimel E; 5th EORTC Quality of Life in Cancer Clinical Trials Conference Faculty (**van de Poll-Franse LV**). Current state of quality of life and patient-reported outcomes research. *Eur J Cancer.* 2019 Sep 24;121:55-63. doi: 10.1016/j.ejca.2019.08.016. [Epub ahead of print]
Impactfactor: 6,680

Campschroer MT, Zhu X, **Vernooij R**, Lock T. Re: What is the role of α -blockers for medical expulsive therapy? Results from a meta-analysis of 60 randomized trials and over 9500 patients. *Urology.* 2019 Feb 28. pii: S0090-4295(19)30211-0. doi: 10.1016/j.urology.2019.02.020. [Epub ahead of print] No abstract available.
Impactfactor: 1,861

de Man Y, Atsma F, Oosterveld-Vlug MG, **Brom L**, Onwuteaka-Philipsen BD, Westert GP, Groenewoud AS. The Intensity of Hospital Care Utilization by Dutch Patients With Lung or Colorectal Cancer in their Final Months of Life. *Cancer Control.* 2019 Jan-Dec;26(1):1073274819846574. doi: 10.1177/1073274819846574.
Impactfactor: 1,990

Dijksterhuis WP, Stroes CI, Tan WL, Ithimakin S, Calles A, **van Oijen MG, Verhoeven RH**, Barriuso J, Oosting SF, Kolarevic Ivankovic D, Furness AJS, Bozovic-Spasojevic I, Gomez-Roca C, van Laarhoven HW. From presentation to paper: gender disparities in oncological research. *Int J Cancer.* 2019 Aug 31. doi: 10.1002/ijc.32660. [Epub ahead of print]
Impactfactor: 4,982

Ezendam NP, Karlsen RV, Christensen J, Tjønneland A, **van de Poll-Franse LV**, von Heymann-Horan A, Johansen C, Bidstrup PE. Do people improve health behavior after their partner is diagnosed with cancer? A prospective study in the Danish diet, Cancer and Health Cohort. *Acta Oncol.* 2019 Feb 1:1-8. doi: 10.1080/0284186X.2018.1557342. [Epub ahead of print]
Impactfactor: 3,298

Gagliardi AR, Armstrong MJ, Bernhardsson S, Fleuren M, Pardo-Hernandez H, **Vernooij RW**, Willson M; Guidelines International Network Implementation Working Group. The Clinician Guideline Determinants Questionnaire was developed and validated to support tailored implementation planning. *J Clin Epidemiol.* 2019 May 29. pii: S0895-4356(18)30894-1. doi: 10.1016/j.jclinepi.2019.05.024. [Epub ahead of print]
Impactfactor: 4,650

Gärtner FR, Portielje JE, Langendam M, Hairwassers D, Agoritsas T, **Gijzen B**, Liefers GJ, Pieterse AH, Stiggelbout AM. Role of patient preferences in clinical practice guidelines: a multiple methods study using guidelines from oncology as a case. *BMJ Open.* 2019 Dec 5;9(12):e032483. doi: 10.1136/bmjopen-2019-032483.
Impactfactor: 2,376

Gatta G, Botta L, Comber H, Dimitrova N, Leinonen MK, Pritchard-Jones K, [Siesling S](#), Trama A, Van Eycken L, [van der Zwan JM](#), [Visser O](#), Zagar T, Capocaccia R. The European study on centralisation of childhood cancer treatment. *Eur J Cancer*. 2019 May 24;115:120-127. doi: 10.1016/j.ejca.2019.04.024. [Epub ahead of print]
Impactfactor: 6,680

Halmos GB, Plate CMA, Krenz G, Molenbuur B, Dikkers FG, [van Dijk BA](#), Wachters JE. Predictors for failure of supraglottic superimposed high-frequency jet ventilation during upper airway surgery in adult patients; a retrospective cohort study of 224 cases. *Clin Otolaryngol*. 2019 Oct 19. doi: 10.1111/coa.13465. [Epub ahead of print]
Impactfactor: 2,377

Han MA, Zeraatkar D, Guyatt GH, [Vernooij RW](#), El Dib R, Zhang Y, Algarni A, Leung G, Storman D, Valli C, Rabassa M, Rehman N, Parvizian MK, Zworth M, Bartoszko JJ, Lopes LC, Sit D, Bala MM, Alonso-Coello P, Johnston BC. Reduction of Red and Processed Meat Intake and Cancer Mortality and Incidence: A Systematic Review and Meta-analysis of Cohort Studies. *Ann Intern Med*. 2019 Oct 1. doi: 10.7326/M19-0699. [Epub ahead of print]
Impactfactor: 19,315

Husson O, [de Rooij BH](#), Kieffer J, [Oerlemans S](#), [Mols F](#), Aaronson NK, van der Graaf WTA, [van de Poll-Franse LV](#). The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry. *Oncologist*. 2019 Oct 31. pii: theoncologist.2019-0348. doi: 10.1634/theoncologist.2019-0348. [Epub ahead of print] Review.
Impactfactor: 5,252

Johnston BC, Alonso-Coello P, Bala MM, Zeraatkar D, Rabassa M, Valli C, Marshall C, El Dib R, [Vernooij RW](#), Vandvik PO, Guyatt GH. Correction to: Methods for trustworthy nutritional recommendations NutriRECS (Nutritional Recommendations and accessible Evidence summaries Composed of Systematic reviews): a protocol. *BMC Med Res Methodol*. 2019 Dec 17;19(1):240. doi: 10.1186/s12874-019-0888-4. Impactfactor: 2,509

Johnston BC, Seivenpiper JL, [Vernooij RW](#), de Souza RJ, Jenkins DJ, Zeraatkar D, Bier DM, Guyatt GH. The Philosophy of Evidence-Based Principles and Practice in Nutrition. *Mayo Clin Proc Innov Qual Outcomes*. 2019 May 27;3(2):189-199. doi: 10.1016/j.mayocpiqo.2019.02.005. eCollection 2019 Jun. Review.
Impactfactor: 7,091

Johnston BC, Zeraatkar D, Han MA, [Vernooij RW](#), Valli C, El Dib R, Marshall C, Stover PJ, Fairweather-Taitt S, Wójcik G, Bhatia F, de Souza R, Brotons C, Meerpohl JJ, Patel CJ, Djulbegovic B, Alonso-Coello P, Bala MM, Guyatt GH. Unprocessed Red Meat and Processed Meat Consumption: Dietary Guideline Recommendations From the Nutritional Recommendations (NutriRECS) Consortium. *Ann Intern Med*. 2019 Oct 1. doi: 10.7326/M19-1621. [Epub ahead of print]
Impactfactor: 19,315

Klaver KM, [Duijts SF](#), Engelhardt EG, Geusgens CA, Aarts MJ, Ponds RW, van der Beek AJ, Schagen SB. Cancer-related cognitive problems at work: experiences of survivors and professionals. *J Cancer Surviv*. 2019 Nov 25. doi: 10.1007/s11764-019-00830-5. [Epub ahead of print]
Impactfactor: 3,585

Leonardi-Bee J, Flohr C, van Zuuren EJ, Le Cleach L, [Hollestein LM](#). Common methodological pitfalls and new developments in systematic review meta-analyses. *Br J Dermatol*. 2019 Oct;181(4):649-651. doi: 10.1111/bjd.18336. No abstract available.
Impactfactor: 6,714

[Luijten JC](#), Vugts G, Nieuwenhuijzen GA, Luyer MD. The Importance of the Microbiome in Bariatric Surgery: a Systematic Review. *Obes Surg*. 2019 Apr 13. doi: 10.1007/s11695-019-03863-y. [Epub ahead of print] Review.
Impactfactor: 3,603

Neeffjes EC, van der Vorst MJ, **Boddaert MS**, Verdegaal BA, Beeker A, Teunissen SC, Beekman AT, Zuurmond WW, Berkhof J, Verheul HM. Accuracy of the Delirium Observational Screening Scale (DOS) as a screening tool for delirium in patients with advanced cancer. *BMC Cancer*. 2019 Feb 19;19(1):160. doi: 10.1186/s12885-019-5351-8. Impactfactor: 2,933

Oldemenger WH, Lucas A, van der Werff GF, Webber K, Visser D, van der Velden AW, **van der Rijt CC**. Validation of the Dutch version of the Breakthrough Pain Assessment Tool in Patients with Cancer. *J Pain Symptom Manage*. 2019 Dec 23. pii: S0885-3924(19)30712-2. doi: 10.1016/j.jpainsymman.2019.12.009. [Epub ahead of print] Impactfactor: 3,378

Pesonen JS, **Vernooij RW**, Cartwright R, Aoki Y, Agarwal A, Mangera A, Markland AD, Tsui JF, Santti H, Griebing TL, Pryalukhin AE, Riikonen J, Tähtinen RM, Vaughan CP, Johnson TM 2nd, Heels-Ansdell D, Guyatt GH, Tikkinen KAO. The Impact of Nocturia on Falls and Fractures: A Systematic Review and Meta-Analysis. *J Urol*. 2019 Jul 26:101097JU0000000000000459. doi: 10.1097/JU.0000000000000459. [Epub ahead of print] Impactfactor: 5,647

Pesonen JS, Cartwright R, **Vernooij RW**, Aoki Y, Agarwal A, Mangera A, Markland AD, Tsui JF, Santti H, Griebing TL, Pryalukhin AE, Riikonen J, Tähtinen RM, Vaughan CP, Johnson TM 2nd, Auvinen A, Heels-Ansdell D, Guyatt GH, Tikkinen KA. The Impact of Nocturia on Mortality: A Systematic Review and Meta-Analysis. *J Urol*. 2019 Jul 31:101097JU0000000000000463. doi: 10.1097/JU.0000000000000463. [Epub ahead of print] Impactfactor: 5,647

Schoormans D, Husson O, **Oerlemans S**, **Ezendam NP**, **Mols F**. Having co-morbid cardiovascular disease at time of cancer diagnosis: already one step behind when it comes to HRQoL? *Acta Oncol*. 2019 Aug 7:1-8. doi: 10.1080/0284186X.2019.1648861. [Epub ahead of print] Impactfactor: 3,298

Smith TG, Dunn ME, Levin KY, Tsakraklides SP, Mitchell SA, **van de Poll-Franse LV**, Ward KC, Wiggins CL, Wu XC, Hurlbert M, Aaronson NK. Cancer survivor perspectives on sharing patient-generated health data with central cancer registries. *Qual Life Res*. 2019 Aug 9. doi: 10.1007/s11136-019-02263-0. [Epub ahead of print] Impactfactor: 2,488

Song Y, Darzi A, Ballesteros M, Martínez García L, Alonso-Coello P, Arayssi T, Bhaumik S, Chen Y, Cluzeau F, Gherzi D, Padilla PF, Langlois EV, Schünemann HJ, **Vernooij RW**, Akl EA. Extending the RIGHT statement for reporting adapted practice guidelines in healthcare: the RIGHT-Ad@pt Checklist protocol. *BMJ Open*. 2019 Sep 24;9(9):e031767. doi: 10.1136/bmjopen-2019-031767. Impactfactor: 2,376

Spelten ER, **Lammens CR**, Engelen V, Duijts SF. An inventory of psychosocial oncological interventions in The Netherlands: identifying availability, gaps, and overlap in care provision. *J Psychosoc Oncol*. 2019 Jul 5:1-27. doi: 10.1080/07347332.2019.1626965. [Epub ahead of print] Impactfactor: 1,197

Teepen JC, Kremer LC, van der Heiden-van der Loo M, Tissing WJ, van der Pal HJ, van den Heuvel-Eibrink MM, Loonen JJ, Louwerens M, Versluys B, van Dulmen-den Broeder E, **Visser O**, Maduro JH, van Leeuwen FE, Ronckers CM; DCOG-LATER Study Group. Clinical characteristics and survival patterns of subsequent sarcoma, breast cancer, and melanoma after childhood cancer in the DCOG-LATER cohort. *Cancer Causes Control*. 2019 Jul 12. doi: 10.1007/s10552-019-01204-z. [Epub ahead of print] Impactfactor: 2,3

Valli C, Rabassa M, Johnston BC, Kuijpers R, Prokop-Dorner A, Zajac J, Storman D, Storman M, Bala MM, Solà I, Zeraatkar D, Han MA, **Vernooij RW**, Guyatt GH, Alonso-Coello P; NutriRECS Working Group. Health-Related Values and Preferences Regarding Meat Consumption: A Mixed-Methods Systematic Review. *Ann Intern Med*. 2019 Oct 1. doi: 10.7326/M19-1326. [Epub ahead of print] Impactfactor: 19,315

van Abbema D, **Vissers PA**, Vos-Geelen J, **Lemmens VE**, Janssen-Heijnen M, Tjan-Heijnen V. Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer. *Cancers (Basel)*. 2019 Aug 23;11(9). pii: E1239. doi: 10.3390/cancers11091239. Impactfactor: 6,162

van der Hout A, van Uden-Kraan CF, Holtmaat K, Jansen F, Lissenberg-Witte BI, Nieuwenhuijzen GA, Hardillo JA, Baatenburg de Jong RJ, Tiren-Verbeet NL, Sommeijer DW, de Heer K, Schaar CG, Sedee RE, Bosscha K, van den Brekel MW, Petersen JF, Westerman M, Honings J, Takes RP, Houtenbos I, van den Broek WT, de Bree R, Jansen P, Eerenstein SE, Leemans CR, Zijlstra JM, Cuijpers P, **van de Poll-Franse LV**, Verdonck-de Leeuw IM. Role of eHealth application Oncokompas in supporting self-management of symptoms and health-related quality of life in cancer survivors: a randomised, controlled trial. *Lancet Oncol*. 2019 Dec 11. pii: S1470-2045(19)30675-8. doi: 10.1016/S1470-2045(19)30675-8. [Epub ahead of print] Impactfactor: 35,386

van der Vorst MJ, Neefjes EC, **Boddaert MS**, Verdegaal BA, Beeker A, Teunissen SC, Beekman AT, Wilschut JA, Berkhof J, Zuurmond WW, Verheul HM. Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. *Oncologist*. 2019 Dec 4. pii: theoncologist.2019-0470. doi: 10.1634/theoncologist.2019-0470. [Epub ahead of print] Impactfactor: 5,252

van der Willik KD, Rüter R, van Rooij FJ, Heemst JV, **Hogewoning SJ**, **Timmermans KC**, **Visser O**, Schagen SB, Ikram MA, Stricker BH. Ascertainment of cancer in longitudinal research: the concordance between the Rotterdam Study and the Netherlands Cancer Registry. *Int J Cancer*. 2019 Oct 23. doi: 10.1002/ijc.32750. [Epub ahead of print] Impactfactor: 4,982

van Eenbergen MC, Vromans RD, Boll D, Kil PJ, Vos CM, Krahmer EJ, **Mols F**, **van de Poll-Franse LV**. Changes in internet use and wishes of cancer survivors: A comparison between 2005 and 2017. *Cancer*. 2019 Oct 3. doi: 10.1002/cncr.32524. [Epub ahead of print] Impactfactor: 6,102

van Eenbergen MC, **van den Hurk C**, **Mols F**, **van de Poll-Franse LV**. Usability of an online application for reporting the burden of side effects in cancer patients. *Support Care Cancer*. 2019 Jan 17. doi: 10.1007/s00520-019-4639-1. [Epub ahead of print] Impactfactor: 2,754

van Nuenen FM, **Donofrio SM**, **Tuinman MA**, van de Wiel HB, **Hoekstra-Weebers JE**. Effects on patient-reported outcomes of "Screening of Distress and Referral Need" implemented in Dutch oncology practice. *Support Care Cancer*. 2019 Nov 28. doi: 10.1007/s00520-019-05140-1. [Epub ahead of print] Impactfactor: 2,754

van Vliet LM, de Veer AJ, **Raijmakers NJ**, Francke A. Is Information Provision About Benefits and Risks of Treatment Options Associated with Receiving Person-Centered Care: A Survey among Incurably Ill Cancer Patients. *J Palliat Med*. 2019 Jan 24. doi: 10.1089/jpm.2018.0591. [Epub ahead of print] Impactfactor: 2,477

van Vulpen JK, Sweegers MG, Peeters PH, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, Galvão DA, Chinapaw MJ, Steindorf K, Irwin ML, Stuiver MM, Hayes S, Griffith KA, Mesters I, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Schmidt ME, Ulrich CM, van Beurden M, Oldenburg HS, Sonke GS, van Harten WH, Schmitz KH, Winters-Stone KM, **Velthuis MJ**, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-de Leeuw IM, Brug J, May AM, Buffart LM. *Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data*. *Med Sci Sports Exerc*. 2019 Sep 12. doi: 10.1249/MSS.0000000000002154. [Epub ahead of print] Impactfactor: 4,478

van Walree IC, Vondeling AM, **Vink GR**, van Huis-Tanja LH, Emmelot-Vonk MH, Bellera C, Soubeyran P, Hamaker ME. Development of a self-reported version of the G8 screening tool. *J Geriatr Oncol*. 2019 Aug 30. pii: S1879-4068(19)30265-6. doi: 10.1016/j.jgo.2019.08.011. [Epub ahead of print] Impactfactor: 3,164

Vernooij RW, Zeraatkar D, Han MA, El Dib R, Zworth M, Milio K, Sit D, Lee Y, Gomaa H, Valli C, Swierz MJ, Chang Y, Hanna SE, Brauer PM, Sievenpiper J, de Souza R, Alonso-Coello P, Bala MM, Guyatt GH, Johnston BC. Patterns of Red and Processed Meat Consumption and Risk for Cardiometabolic and Cancer Outcomes: A Systematic Review and Meta-analysis of Cohort Studies. *Ann Intern Med.* 2019 Oct 1. doi: 10.7326/M19-1583. [Epub ahead of print]
Impactfactor: 19,315

Wagner AD, Oertelt-Prigione S, Adjei A, Buclin T, Cristina V, Csajka C, Coukos G, Dafni U, Dotto GP, Ducreux M, Fellay J, Haanen J, Hocquet A, Klinge I, **Lemmens VE**, Letsch A, Mauer M, Moehler M, Peters S, Özdemir BC. *Gender Medicine and Oncology: Report and consensus of an ESMO Workshop.* *Ann Oncol.* 2019 Oct 15. pii: mdz414. doi: 10.1093/annonc/mdz414. [Epub ahead of print]
Impactfactor: 14,196

Walraven JE, Desar IM, Hoeven van der JJ, **Aben KK**, Hillegersberg van R, Rasch CR, **Lemmens VE**, **Verhoeven RH**. Analysis of 105.000 patients with cancer: have they been discussed in oncologic multidisciplinary team meetings? A nationwide population-based study in the Netherlands. *Eur J Cancer.* 2019 Sep 26;121:85-93. doi: 10.1016/j.ejca.2019.08.007. [Epub ahead of print]
Impactfactor: 6,680

Zeraatkar D, Johnston BC, Bartoszko J, Cheung K, Bala MM, Valli C, Rabassa M, Sit D, Milio K, Sadeghirad B, Agarwal A, Zea AM, Lee Y, Han MA, **Vernooij RW**, Alonso-Coello P, Guyatt GH, El Dib R. Effect of Lower Versus Higher Red Meat Intake on Cardiometabolic and Cancer Outcomes: A Systematic Review of Randomized Trials. *Ann Intern Med.* 2019 Oct 1. doi: 10.7326/M19-0622. [Epub ahead of print]
Impactfactor: 19,315

Zeraatkar D, Han MA, Guyatt GH, **Vernooij RW**, El Dib R, Cheung K, Milio K, Zworth M, Bartoszko JJ, Valli C, Rabassa M, Lee Y, Zajac J, Prokop-Dorner A, Lo C, Bala MM, Alonso-Coello P, Hanna SE, Johnston BC. Red and Processed Meat Consumption and Risk for All-Cause Mortality and Cardiometabolic Outcomes: A Systematic Review and Meta-analysis of Cohort Studies. *Ann Intern Med.* 2019 Oct 1. doi: 10.7326/M19-0655. [Epub ahead of print]
Impactfactor: 19,315

1.2 Overige publicaties

Dekker NR, Stigt JA, **Visser O**, Netters FJ, Koornstra RH, de Groot JW. Immunotherapie voor kanker: van medische doorbraak naar toepassing in de dagelijkse praktijk. *Ned Tijdsch Geneesk* 2019; 163:D3782.

Siesling S, **Visser O**, **Aarts MJ**, **Verhoeven RH**, **Aben KK**, **Dinomhamed AG**, **van Dijk BA**, **van der Aa MA**, **Louwman MW**, **Lemmens VE**. Kankerbestrijding in Nederland: de stand van zaken. *Ned Tijdsch Geneesk* 2019;163:D4150.

van den Hurk CJ, Keizer-Heldens P, Raats I, **Hoeijmakers K**, **Mols F**. Improving information provision on chemotherapy-induced alopecia and scalp cooling: a comprehensive approach including a website and web-based decision tool. *Asia Pac J Oncol Nurs* 2019 Aug; 6(4):336-342.

van der Graaf WT, Jansen R, **Manten-Horst E**. Zorg voor adolescenten en jongvolwassenen met kanker: de rol van een landelijk zorgnetwerk. *Ned Tijdsch Geneesk* 2019;163:D3767.

van Diest PJ, Huisman A, van Ekris J, Meijer J, Willems S, Hofhuis H, **Verbeek X**, van der Wel M, Vos S, Leguit R, van den Brand M, Hebeda K, Grünberg K. Pathology Image Exchange: The Dutch Digital Pathology Platform for Exchange of Whole-Slide Images for Efficient Teleconsultation, Telerevision, and Virtual Expert Panels. *JCO Clin Cancer Inform.* 2019 Jun;3:1-7. doi: 10.1200/CCI.18.00146.

Verberne S, Batenburg A, Sanders R, **van Eenbergen MC**, Das E, Lambooy MS. Analyzing Empowerment Processes Among Cancer Patients in an Online Community: A Text Mining Approach. *JMIR Cancer.* 2019 Apr 17;5(1):e9887. doi: 10.2196/cancer.9887.

1.3 Proefschriften en promoties

van Veen MR. Improving information provision on nutrition and cancer: for cancer survivors and health professionals. Wageningen: Wageningen University; 18 september 2019. Co-promotor: **S Beijer**. Overige leden: CP de Groot, **LV van de Poll-Franse**, N Hoogerbrugge, W Kroeze.

1.4 Posters

Hommes S, Clouth F, Vromans R, **Geleijnse G,** Pauws S, Vermunt J, **van de Poll-Franse LV,** Krahmer E. Data-driven shared decision-making on cancer treatment. Big Data: Conference for NWO calls in Data2Person and Big Data & Health; 2 oktober 2019; Amersfoort.

van den Hurk CJ. Hair loss through chemotherapy is not inevitable. European Oncology Convention; 26-27 maart 2019; Birmingham.

van den Hurk CJ. Scalp cooling for chemotherapy alopecia. JAAD, American Academy of Dermatology Annual Meeting; 1-5 maart 2019; Washington.

van den Hurk CJ, Dercksen W, Vriens B, Breed W. Scalp cooling proved to be successful in the prevention of alopecia in ≥ 7000 patients with solid tumors. NCCN, National Comprehensive Cancer Network Annual Conference; 3-5 maart 2019; Orlando.

1.5 Presentaties en abstracts

Beijer S. Diet and cancer: diet during treatment. Opleidingsblok Wageningen University & Research; oktober 2019; Wageningen.

Buiting HM, Botman F, van der Velden LA, **Brom L,** van Heest F, de Mol P, Bakker T. Experiences of general practitioners and medical specialists with incurable cancer patients with a protracted disease trajectory: a focus group study. ASCO, American Society of Clinical Oncology Annual Meeting; 31 mei-4 juni 2019; Chicago.

Ezendam NP. Address needs of patients with low literacy skills in daily clinical practice: adapt language level of EORTC questionnaires. EORTC Quality of Life Group Autumn Meeting; 25-27 september 2019; Napels.

Geleijnse G, Martin F, Karaalioglu M. Distributed learning at IKNL: infrastructure, algorithms and on-going studies...and an extra slide about our Cox algorithm. DataSHIELD workshop; 11 september 2019; Newcastle.

Geleijnse G, Worm D. Enabling privacy-preserving analyses on federated healthcare data. Dcypher symposium; 3 december 2019; Utrecht.

Hommes S, van der Lee C, **Clouth F,** Vermunt J, **Verbeek X,** Krahmer E. A Personalized Data-to-Text Support Tool for Cancer Patients. INLG, International conference on Natural Language Generation; 29 oktober-1 november 2019; Tokyo.

Knoors D. Federated Learning at IKNL. ELIXIR Innovation and SME Forum; 10 oktober 2019; Utrecht.

Knoors D. Privacy Engineering at IKNL. Computational Privacy Group at Imperial College; 6 november 2019; Londen.

Kristjansson RP, Benonisdottir S, Oddsson A, Galesloot TE, Thorleifsson G, **Aben KK,** Davidsson OB, Jonsson S, Arnadottir GA, Alexandersson KF, Jensson BO, Walters G, Sigurdsson JK, Sigurdsson S, Holm H, Arnar DO, Thorgeirsson G, Alexiusdottir K, Jonsdottir I, Thorsteinsdottir U, Kiemeny LA, Jonsson T, Gudbjartsson DF, Rafnar T, Sulem P, Stefansson K. Sequence variant at 4q25 near PITX2 associates with appendicitis. ESHG, European Society of Human Genetics Conference; 15-18 juni 2019; Gothenburg.

van den Hurk CJ, Achmadzai S, Breed W. Influence of infusion times and wetting the hair on scalp cooling efficacy to prevent alopecia. MASCC/ISOO annual meeting; 21-23 juni 2019; San Francisco, California.

van den Hurk CJ, Dercksen MW, Nortier JW, Breed W. Learning from best scalp cooling practices in a registry: differences in results from n>7000 patients with solid tumors. ASCO, American Society of Clinical Oncology Annual Meeting; 31 mei-4 juni 2019; Chicago.

van den Hurk CJ. Scalp cooling for prevention of chemotherapy-induced alopecia: the 'real world' experience. MASCC/ISOO annual meeting; 21-23 juni 2019; San Francisco, California.

van den Hurk CJ, van Eenbergen ME, Mols F, Becker M, van Doorne-Nagtegaal H, van der Werf J, **van de Poll-Franse LV**. Usability of an online application for monitoring cancer patient-reported burden of side effects in daily clinical practice. MASCC/ISOO annual meeting; 21-23 juni 2019; San Francisco, California.

van Walree IC, Vondeling A, **Vink GR**, van Huis-Tanja LH, Emmelot-Vonk MH, Bellera C, Soubeyran P, Hamaker ME. Development of a self-reported version of the G8 screening tool. SIOG, Society of Geriatric Oncology Annual Conference; 14-16 november 2019; Genève.

Vromans R, van Eenbergen ME, Geleijnse G, Pauws S, **van de Poll-Franse LV**, Kraemer E. Communicating personalized cancer statistics: challenges and opportunities. Etmaal van de Communicatiewetenschap; 7-8 februari 2019; Nijmegen.

Vromans R, Hommes S, Clouth F, Pauws S, Vermunt J, **Geleijnse G, van Eenbergen ME, Verbeek X, van de Poll-Franse LV**, Kraemer E. Data-driven shared decision-making on cancer treatment. ICT.Open Conferentie; 19-20 maart 2019; Hilversum.

2 Borstkanker

2.1 Publicaties met impactfactor

Beek MA, Gobardhan PD, Klompenhouwer EG, Menke-Pluijmers MB, Steenvoorde P, Merkus JW, Rutten HJ, **Voogd AC**, Luiten EJ. A patient- and assessor-blinded randomized controlled trial of axillary reverse mapping (ARM) in patients with early breast cancer. *Eur J Surg Oncol*. 2019 Aug 5. pii: S0748-7983(19)30615-8. doi: 10.1016/j.ejso.2019.08.003. [Epub ahead of print]
Impactfactor: 3,379

de Boer AZ, Bastiaannet E, de Glas NA, Marang-van de Mheen PJ, Dekkers OM, **Siesling S, de Munck L, de Ligt KM**, Portielje JE, Liefers GJ. Effectiveness of radiotherapy after breast-conserving surgery in older patients with T1-2N0 breast cancer. *Breast Cancer Res Treat*. 2019 Aug 26. doi: 10.1007/s10549-019-05412-8. [Epub ahead of print]
Impactfactor: 3,471

de Boer AZ, van der Hulst HC, de Glas NA, Marang-van de Mheen PJ, **Siesling S, de Munck L, de Ligt KM**, Portielje JE, Bastiaannet E, Liefers GJ. Impact of Older Age and Comorbidity on Locoregional and Distant Breast Cancer Recurrence: A Large Population-Based Study. *Oncologist*. 2019 Sep 12. pii: theoncologist.2019-0412. doi: 10.1634/theoncologist.2019-0412. [Epub ahead of print]
Impactfactor: 5,252

de Glas N, Bastiaannet E, de Boer A, **Siesling S**, Liefers GJ, Portielje J. Improved survival of older patients with advanced breast cancer due to an increase in systemic treatments: a population-based study. *Breast Cancer Res Treat*. 2019 Jul 19. doi: 10.1007/s10549-019-05356-z. [Epub ahead of print]
Impactfactor: 3,471

de Ligt KM, van Egdom LS, Koppert LB, **Siesling S**, van Til JA. Opportunities for personalised follow-up care among patients with breast cancer: A scoping review to identify preference-sensitive decisions. *Eur J Cancer Care (Engl)*. 2019 May 9:e13092. doi: 10.1111/ecc.13092. [Epub ahead of print] Review.
Impactfactor: 2,421

de Ligt KM, Heins M, **Verloop J**, Smorenburg CH, Korevaar JC, **Siesling S**. Patient-reported health problems and healthcare use after treatment for early-stage breast cancer. *Breast*. 2019 Apr 4;46:4-11. doi: 10.1016/j.breast.2019.03.010. [Epub ahead of print]
Impactfactor: 3,494

de Ligt KM, Heins M, **Verloop J, Ezendam NP**, Smorenburg CH, Korevaar JC, **Siesling S**. The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors. *Breast Cancer Res Treat*. 2019 Sep 11. doi: 10.1007/s10549-019-05433-3. [Epub ahead of print]
Impactfactor: 3,471

Giardiello D, Steyerberg EW, Hauptmann M, Adank MA, Akdeniz D, Blomqvist C, Bojesen SE, Bolla MK, Brinkhuis M, Chang-Claude J, Czene K, Devilee P, Dunning AM, Easton DF, Eccles DM, Fasching PA, Figueroa J, Flyger H, García-Closas M, Haeberle L, Haiman CA, Hall P, Hamann U, Hopper JL, Jager A, Jakubowska A, Jung A, Keeman R, Kramer I, Lambrechts D, Le Marchand L, Lindblom A, Lubiński J, Manoochehri M, Mariani L, Nevanlinna H, Oldenburg HS, Pelders S, Pharoah PD, Shah M, **Siesling S**, Smit VTHBM, Southey MC, Tapper WJ, Tollenaar RA, van den Broek AJ, van Deurzen CH, van Leeuwen FE, van Ongeval C, Van't Veer LJ, Wang Q, Wendt C, Westenend PJ, Hooning MJ, Schmidt MK. Prediction and clinical utility of a contralateral breast cancer risk model. *Breast Cancer Res*. 2019 Dec 17;21(1):144. doi: 10.1186/s13058-019-1221-1.
Impactfactor: 5,676

Heeg E, Marang-van de Mheen PJ, **van Maaren MC, Schreuder K**, Tollenaar RA, **Siesling S**, Bos ME, Vrancken Peeters MT. Association between Initiation of Adjuvant Chemotherapy Beyond 30 Days Following Surgery and Overall Survival Among Patients With Triple-Negative Breast Cancer. *Int J Cancer*. 2019 Nov 12. doi: 10.1002/ijc.32788. [Epub ahead of print]
Impactfactor:4,982

Hoveling LA, van Maaren MC, Hueting T, Strobbe LJ, Hendriks MP, Sonke GS, **Siesling S**. Validation of the online prediction model CancerMath in the Dutch breast cancer population. *Breast Cancer Res Treat*. 2019 Aug 30. doi: 10.1007/s10549-019-05399-2. [Epub ahead of print]
Impactfactor: 3,471

Kamali P, van Bommel A, Becherer B, Cooter R, Mureau MA, Pusic A, **Siesling S**, van der Hulst RR, Lin SJ, Rakhorst H. Immediate Breast Reconstruction in The Netherlands and the United States: A Proof-of-Concept to Internationally Compare Quality of Care Using Cancer Registry Data. *Plast Reconstr Surg*. 2019 Oct;144(4):565e-574e. doi: 10.1097/PRS.0000000000006011.
Impactfactor: 3,946

Keymeulen KB, Geurts SM, Lobbes MB, Heuts EM, Duijm LE, Kooreman LF, **Voogd AC**, Tjan-Heijnen VC. Population-based study of the effect of preoperative breast MRI on the surgical management of ductal carcinoma in situ. *Br J Surg*. 2019 Aug 6. doi: 10.1002/bjs.11299. [Epub ahead of print]
Impactfactor: 5,572

Kramer I, Schaapveld M, Oldenburg HS, Sonke GS, McCool D, van Leeuwen FE, Van de Vijver KK, Russell NS, Linn SC, **Siesling S**, Menke-van der Houven van Oordt CW, Schmidt MK. The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype. *J Natl Cancer Inst*. 2019 Jan 30. doi: 10.1093/jnci/djz010. [Epub ahead of print]
Impactfactor: 10,211

Luiten JD, Korte B, **Voogd AC**, Vreuls W, Luiten EJ, Strobbe LJ, Rutten MJ, Plaisier ML, Lohle PN, Hooijen MJ, Tjan-Heijnen VC, Duijm LE. Trends in frequency and outcome of high-risk breast lesions at core needle biopsy in women recalled at biennial screening mammography, a multi-institutional study. *Int J Cancer*. 2019 Apr 19. doi: 10.1002/ijc.32353. [Epub ahead of print]
Impactfactor: 4,982

Luiten JD, **Voogd AC**, Tjan-Heijnen VC, Wesseling J, Luiten EJ, Duijm LE. Utility of diagnostic breast excision biopsies during two decades of screening mammography. *Breast*. 2019 Jun 1;46:157-162. doi: 10.1016/j.breast.2019.05.018. [Epub ahead of print]
Impactfactor: 3,494

Overbeek JA, van Herk-Sukel MP, **Vissers PA**, van der Heijden AA, Bronsveld HK, Herings RM, Schmidt MK, Nijpels G. Type 2 Diabetes, but not Insulin (Analog) treatment, is associated with more advanced stages of breast cancer: a national linkage of cancer and pharmacy registries. *Diabetes Care*. 2019 Jan 24. pii: dc182146. doi: 10.2337/dc18-2146. [Epub ahead of print]
Impactfactor: 15,270

Poodt IG, Walstra CJ, Vugts G, Maaskant-Braat AJ, **Voogd AC**, Schipper RJ, Nieuwenhuijzen GA; Sentinel Node And Recurrent Breast Cancer (SNARB) study group. Low risk of development of a regional recurrence after an unsuccessful repeat sentinel lymph node biopsy in patients with ipsilateral breast tumor recurrence. *Ann Surg Oncol*. 2019 Mar 8. doi: 10.1245/s10434-019-07272-4. [Epub ahead of print]
Impactfactor: 3,681

Poodt IG, Vugts G, Schipper RJ, Roumen RM, Rutten HJ, Maaskant-Braat AJ, **Voogd AC**, Nieuwenhuijzen GA; Sentinel Node and Recurrent Breast Cancer (SNARB) study group. Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence. *Br J Surg*. 2019 Apr;106(5):574-585. doi: 10.1002/bjs.11097.
Impactfactor: 5,572

Poodt IG, Schipper RJ, de Greef BT, Vugts G, Maaskant-Braat AJ, Jansen FH, Wyndaele DN, **Voogd AC**, Nieuwenhuijzen GA; Sentinel Node And Recurrent Breast Cancer (SNARB) Research Group. Screening for distant metastases in patients with ipsilateral breast tumor recurrence: the impact of different imaging modalities on distant recurrence-free interval. *Breast Cancer Res Treat*. 2019 Apr 6. doi: 10.1007/s10549-019-05205-z. [Epub ahead of print]
Impactfactor: 3,471

Rombouts AJ, Huising J, Hugen N, **Siesling S**, Poortmans PM, Nagtegaal ID, de Wilt JH. Assessment of Radiotherapy-Associated Angiosarcoma After Breast Cancer Treatment in a Dutch Population-Based Study. *JAMA Oncol*. 2019 Jan 24. doi: 10.1001/jamaoncol.2018.6643. [Epub ahead of print] No abstract available.

Impactfactor: 22,416

Samiei S, van Kaathoven BN, Boersma L, Granzier RWY, **Siesling S**, Engelen SM, **de Munck L**, van Kuijk SM, van der Hulst RR, Lobbes MB, Smidt ML, van Nijnatten TJ. Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction. *Ann Surg Oncol*. 2019 Jul 29. doi: 10.1245/s10434-019-07643-x. [Epub ahead of print]

Impactfactor: 3,681

Schreuder K, Middelburg JG, **Aarts MJ**, Merkus JW, Poortmans PM, Jobsen JJ, **Siesling S**, Struikmans H. An actualised population-based study on the use of radiotherapy in breast cancer patients in the Netherlands. *Breast J*. 2019 Jun 4. doi: 10.1111/tbj.13376. [Epub ahead of print]

Impactfactor: 2,433

Schreuder K, Kuijer A, Bentum S, van Dalen T, **Siesling S**. Use and Impact of the 21-Gene Recurrence Score in Relation to the Clinical Risk of Developing Metastases in Early Breast Cancer Patients in the Netherlands. *Public Health Genomics*. 2019 Jan 16;21(1-2):1-8. doi: 10.1159/000495742. [Epub ahead of print]

Impactfactor: 1,527

Tamminga SJ, Coenen P, **Paalman C**, de Boer AGEM, Aaronson NK, Oldenburg HSA, van Leeuwen FE, van der Beek AJ, Duijts SFA, **Schaapveld M**. Factors associated with an adverse work outcome in breast cancer survivors 5-10 years after diagnosis: a cross-sectional study. *J Cancer Surviv*. 2019 Jan 14. doi: 10.1007/s11764-018-0731-7. [Epub ahead of print]

Impactfactor: 3,585

van Bommel AC, Spronk P, Mureau M, **Siesling S**, Smorenburg C, Tollenaar R, Vrancken Peeters MJ, van Dalen T. Breast-Contour-Preserving Procedure as a Multidisciplinary Parameter of Esthetic Outcome in Breast Cancer Treatment in The Netherlands. *Ann Surg Oncol*. 2019 Mar 4. doi: 10.1245/s10434-019-07265-3. [Epub ahead of print]

Impactfactor: 3,681

van den Hoven I, van Klaveren D, Verheувel NC, van la Parra RF, **Voogd AC**, de Roos WK, Bosscha K, Heuts EM, Tjan-Heijnen VC, **Roumen RM**, Steyerberg EW. Predicting the extent of nodal involvement for node positive breast cancer patients: development and validation of a novel tool. *J Surg Oncol*. 2019 Jul 23. doi: 10.1002/jso.25644. [Epub ahead of print]

Impactfactor: 3,114

van Hellemond IE, Smorenburg CH, Peer PG, **Swinkels AC**, Seynaeve CM, van der Sangen MJ, Kroep JR, De Graaf H, Honkoop AH, Erdkamp FL, van den Berkmortel FW, de Boer M, de Roos WK, Linn SC, Imholz AL, Tjan-Heijnen VC; Dutch Breast Cancer Research Group (BOOG). Assessment and Management of Bone Health in Women with Early Breast Cancer Receiving Endocrine Treatment in the DATA Study. *Int J Cancer*. 2019 Feb 12. doi: 10.1002/ijc.32205. [Epub ahead of print]

Impactfactor: 4,982

van Maaren MC, Kneepkens RF, Verbaan J, **Huijgens PC**, **Lemmens VE**, **Verhoeven RH**, **Siesling S**. A conditional model predicting the 10-year annual extra mortality risk compared to the general population: a large population-based study in Dutch breast cancer patients. *PLoS One*. 2019 Jan 24;14(1):e0210887. doi: 10.1371/journal.pone.0210887. eCollection 2019.

Impactfactor: 2,776

van Maaren MC, le Cessie S, Strobbe LJ, Groothuis-Oudshoorn CG, Poortmans PM, **Siesling S**. Different statistical techniques dealing with confounding in observational research: measuring the effect of breast-conserving therapy and mastectomy on survival. *J Cancer Res Clin Oncol*. 2019 Apr 24. doi: 10.1007/s00432-019-02919-x. [Epub ahead of print]

Impactfactor: 3,332

van Steenbeek CD, van Maaren MC, Siesling S, Witteveen A, Verbeek XA, Koffijberg H. Facilitating validation of prediction models: a comparison of manual and semi-automated validation using registry-based data of breast cancer patients in the Netherlands. *BMC Med Res Methodol*. 2019 Jun 8;19(1):117. doi: 10.1186/s12874-019-0761-5. Impactfactor: 2,509

van Steenhoven JE, Kuijer A, Schreuder K, Elias SG, van Diest PJ, van der Wall E, Siesling S, van Dalen T. The Changing Role of Gene-Expression Profiling in the Era of De-escalating Adjuvant Chemotherapy in Early-Stage Breast Cancer. *Ann Surg Oncol*. 2019 Jun 17. doi: 10.1245/s10434-019-07511-8. [Epub ahead of print] Impactfactor: 3,681

van Uden DJ, van Maaren MC, Strobbe LJ, Bult P, van der Hoeven JJ, Siesling S, de Wilt JH, Blanken-Peeters CF. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer. *Breast Cancer Res*. 2019 Oct 17;21(1):113. doi: 10.1186/s13058-019-1201-5. Impactfactor: 5,676

van Uden DJ, van Maaren MC, Bult P, Strobbe LJ, van der Hoeven JJ, Blanken-Peeters CFJM, Siesling S, de Wilt JH. Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer. *Breast Cancer Res Treat*. 2019 Apr 10. doi: 10.1007/s10549-019-05219-7. [Epub ahead of print] Impactfactor: 3,471

Vane MLG, Willemsen MA, van Roozendaal LM, van Kuijk SMJ, Kooreman LFS, Siesling S, de Wilt HHW, Smidt ML. Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients? *Breast Cancer Res Treat*. 2019 Jan 4. doi: 10.1007/s10549-018-05074-y. [Epub ahead of print] Impactfactor: 3,471

Voelkel V, Draeger T, Groothuis-Oudshoorn CG, de Munck L, Hueting T, Gerken M, Klinkhammer-Schalke M, Lavric M, Siesling S. Predicting the risk of locoregional recurrence after early breast cancer: an external validation of the Dutch INFLUENCE-nomogram with clinical cancer registry data from Germany. *J Cancer Res Clin Oncol*. 2019 Mar 29. doi: 10.1007/s00432-019-02904-4. [Epub ahead of print] Impactfactor: 3,332

Vromans RD, Tenfelde K, Pauws S, van Eenbergen MC, Mares-Engelberts I, Velikova G, van de Poll-Franse LV, Krahmer E. Assessing the quality and communicative aspects of patient decision aids for early-stage breast cancer treatment: a systematic review. *Breast Cancer Res Treat*. 2019 Jul 24. doi: 10.1007/s10549-019-05351-4. [Epub ahead of print] Review. Impactfactor: 3,471

Walstra CJ, Schipper RJ, Poodt IG, van Riet YE, Voogd AC, van der Sangen MJ, Nieuwenhuijzen GA. Repeat breast-conserving therapy for ipsilateral breast cancer recurrence: A systematic review. *Eur J Surg Oncol*. 2019 Feb 10. pii: S0748-7983(19)30277-X. doi: 10.1016/j.ejso.2019.02.008. [Epub ahead of print] Review. Impactfactor: 3,379

Witlox L, Velthuis MJ, Boer JH, Steins Bisschop CN, Wall EV, Meulen WJ, Schröder CD, Peeters PH, May AM. Attendance and compliance with an exercise program during localized breast cancer treatment in a randomized controlled trial: The PACT study. *PLoS One*. 2019 May 8;14(5):e0215517. doi: 10.1371/journal.pone.0215517. eCollection 2019. Impactfactor: 2,776

Witlox L, Schagen SB, de Ruiter MB, Geerlings MI, Peeters PHM, Koevoets EW, van der Wall E, Stuijver M, Sonke G, Velthuis MJ, Palen JA, Jobsen JJ, May AM, Monninkhof EM. Effect of physical exercise on cognitive function and brain measures after chemotherapy in patients with breast cancer (PAM study): protocol of a randomised controlled trial. *BMJ Open*. 2019 Jun 20;9(6):e028117. doi: 10.1136/bmjopen-2018-028117. Impactfactor: 2,376

2.2 Overige publicaties

Hendriks MP, [Verbeek XA](#), [van Vegchel T](#), van der Sangen MJ, Strobbe LJ, Merkus JW, Zonderland HM, Smorenburg CH, Jager A, [Siesling S](#). Transformation of the National Breast Cancer Guideline Into Data-Driven Clinical Decision Trees. *JCO Clin Cancer Inform*. 2019 May;3:1-14. doi: 10.1200/CCI.18.00150.

2.3 Proefschriften en promoties

[de Ligt KM](#). Towards personalised breast cancer care: variation in treatment and follow-up from the patients' perspective. Enschede: Universiteit Twente; 13 september 2019. Promotor: [S Siesling](#).

2.4 Boekbijdragen

Verhoeven D, Kaufman C, Mansel R, [Siesling S](#) (editors). Met bijdragen van [Verbeek X](#), [Voogd A](#). Breast cancer: global quality care. Oxford: Oxford University Press, 2019. 432 p.

2.5 Posters

de Boer AZ, de Glas NA, Marang-van de Mheen PJ, Dekkers OM, [Siesling S](#), [de Munck L](#), [de Ligt KM](#), Bastiaannet E, Portielje EA, Liefers GJ. The effect of omission of surgery on survival in patients aged ≥ 80 years with stage 1-2 hormone receptor-positive breast cancer. ESSO, The European Society of Surgical Oncology Congress; 9-11 oktober 2019; Rotterdam.

de Jong V, ter Hoeve N, Opdam M, Vreuls W, Koop E, Varga Z, Willems S, van Deurzen C, Cordoba A, Broeks A, Stathonikos N, [Voogd AC](#), Józwiak K, Hauptmann M, Sonke G, van der Wall E, [Siesling S](#), van Diest P, Linn S, Dackus G. Tumor size and overall survival in a cohort of young (≤ 40 years), NO, systemically untreated breast cancer patients: by the PARADIGM study group. ESMO, European Society for Medical Oncology Breast Cancer Congress; 2-4 mei 2019; Berlijn.

[de Ligt KM](#), Heins M, [Verloop J](#), Smorenburg CH, Korevaar JC, [Siesling S](#). Patient-reported health problems and health care use after treatment for early breast cancer. ESMO, European Society for Medical Oncology Breast Cancer Congress; 2-4 mei 2019; Berlijn.

Heeg E, Marang-van de Mheen PJ, [van Maaren MC](#), [Schreuder K](#), Tollenaar RA, [Siesling S](#), Bos ME, Vrancken-Peeters MT. Association between initiation of adjuvant chemotherapy beyond 30 days following surgery and overall survival among patients with triple-negative breast cancer. ISPOR conference; 2-6 november 2019; Kopenhagen.

Hoveling LA, [van Maaren MC](#), Hueting T, Strobbe LJ, Hendriks MP, Sonke GS, [Siesling S](#). Validation of the online prediction model CancerMath in the Dutch breast cancer population. WEON Conference; 13-14 juni 2019; Groningen.

[Luyendijk M](#), [Vernooij RW](#), Blommestein HM, [Siesling S](#), Uyl-de Groot CA. Quality of studies based on claims data: a systematic review of (cost)-effectiveness studies of systemic therapies in breast cancer. ISPOR conference; 2-6 november 2019; Kopenhagen.

[Luyendijk M](#), [Visser O](#), Blommestein HM, Uyl-de Groot C, [Siesling S](#). 29 years of breast cancer: a timeline of progress in the Netherlands. SABCS, San Antonio Breast Cancer Group Symposium; 10-14 december 2019; San Antonio, Texas.

Steenbruggen TG, van Ramshorst MS, van Werkhoven E, Dezentje VO, Linn SC, [Siesling S](#), Sonke GS. Adjuvant chemotherapy in small node-negative triple-negative breast cancer (TNBC). ASCO annual meeting; 31 mei-4 juni 2019; Chicago, Illinois.

[van Maaren MC](#), Ortega Avila A, van Manen JG, Bart J, Westenend PJ, [Siesling S](#). Classic lobular carcinoma in situ in the Netherlands: a population-based analysis. SABCS, San Antonio Breast Cancer Group Symposium; 10-14 december 2019; San Antonio, Texas.

van Maaren MC, Hoveling LA, Hueting T, Strobbe LJ, Hendriks MP, Sonke GS, Siesling S. Validation of the online prediction model CancerMath in the Dutch breast cancer population. SABCS, San Antonio Breast Cancer Group Symposium; 10-14 december 2019; San Antonio, Texas.

Voelkel V, Draeger T, Siesling S, Groothuis-Oudshoorn C. INFLUENCE 2.0: a time-dependent model to predict locoregional recurrence and second primaries in early breast cancer patients. ISPOR conference; 2-6 november 2019; Kopenhagen.

Wolbers RG, Bode C, Siemerink EJ, Siesling S, Pieterse ME. Design of a cognitive bias modification eHealth app to improve implicit vitality in breast cancer patients: a co-creation process. SABCS, San Antonio Breast Cancer Group Symposium; 10-14 december 2019; San Antonio, Texas.

2.6 Presentaties en abstracts

de Boer AZ, van der Hulst HC, van der Plas-Krijgsman W, de Glas NA, Marang-van de Mheen PJ, Siesling S, Liefers GJ, Bastiaannet E, Portielje JE. Impact of older age on the locoregional and distant breast cancer recurrence risk: a large population-based study. ESMO, European Society for Medical Oncology Breast Cancer Congress; 2-4 mei 2019; Berlijn.

de Boer AZ, de Glas NA, Marang van de Mheen PJ, Dekkers OM, Siesling S, de Munck L, de Ligt KM, Bastiaannet E. Omission of surgery in patients aged 80 years or older with stage 1-2 hormone receptor-positive breast cancer by comorbidity status. SIOG, Society of Geriatric Oncology Annual Conference; 14-16 november 2019; Genève.

de Boer AZ, Bastiaannet E, de Glas NA, Marang-van de Mheen PJ, Siesling S, de Munck L, de Ligt KM, Portielje JE, Liefers GJ. Time trends in axillary surgery and regional recurrence in older patients with clinically node-negative breast cancer. ESSO, The European Society of Surgical Oncology Congress; 9-11 oktober 2019; Rotterdam.

de Boer AZ, de Glas NA, Marang-van de Mheen PJ, Dekkers OM, Siesling S, Portielje JE, Bastiaannet E, Liefers GJ. Variation in radiotherapy after breast conserving surgery in patients aged 75 years or older between hospitals is not reflected in the locoregional recurrence risk. ESMO, European Society for Medical Oncology Breast Cancer Congress; 2-4 mei 2019; Berlijn.

de Jong V, ter Hoeve N, Opdam M, Vreuls W, Koop E, Varga Z, Willems S, van Deurzen C, Cordoba A, Broeks A, Stathonikos N, Voogd AC, Józwiak K, Hauptmann M, Sonke G, van der Wall E, Siesling S, van Diest P, Linn S, Dackus G. Tumor size and overall survival in a cohort of young (≤ 40 years), NO, systemically untreated breast cancer patients: by the PARADIGM study group. ESMO, European Society for Medical Oncology Breast Cancer Congress; 2-4 mei 2019; Berlijn.

de Ligt KM. Patient-reported health problems and healthcare use after treatment for early-stage breast cancer. Bossche Mamma Congres; 18-19 juni 2019; St. Michielsgestel.

de Ligt KM. The impact of health problems on quality of life in breast cancer survivors. Bossche Mamma Congres; 18-19 juni 2019; St. Michielsgestel.

de Munck L, Siesling S, Fracheboud J, den Heeten GJ, Broeders MJ, de Bock, GH. Studying impact of mammographic screening: large differences in the proportion of advanced-stage breast cancer irrespective of varying definitions. ICSN, International Cancer Screening Conference; 3-5 juni 2019; Rotterdam.

Draeger T, Voelkel V, Groothuis-Oudshoorn C, Lavric M, Veltman J, Dassen A, Boersma L, Witteveen A, Sonke G, Koffijberg H, Siesling S. Applying risk-based follow-up strategies on the Dutch breast cancer population: consequences for care and costs. SABCS, San Antonio Breast Cancer Group Symposium; 10-14 december 2019; San Antonio, Texas.

Gal R, Işgum I, van Velzen SG, Emaus MJ, van den Bongard HJ, Gregorowitsch ML, Blezer EL, Gernaat SA, Lessmann N, Sattler MG, Teske AJ, Penninkhof J, Meijer H, van TolpGeerdink JJ, Pignol JP, Verloop J, Verkooijen IH. Cardiovascular risk assessment based on cardiac calcifications on breast radiotherapy planning CT scans. SABCS, San Antonio Breast Cancer Group Symposium; 10-14 december 2019; San Antonio, Texas.

Heins MJ, **de Ligt KM**, **Verloop J**, **Siesling S**, Korevaar JC. Predicting symptoms and diseases after breast cancer treatment: development of a nomogram. SABCS, San Antonio Breast Cancer Group Symposium; 10-14 december 2019; San Antonio, Texas.

Hoveling LA, **van Maaren MC**, Hueting T, Strobbe LJ, Hendriks MP, Sonke GS, **Siesling S**. Validation of the online prediction model CancerMath in the Dutch breast cancer population. WEON Conference; 13-14 juni 2019; Groningen.

Luyendijk M, **Vernooij RW**, Blommestein HM, **Siesling S**, Uyl-de Groot CA. Assessment of studies evaluating incremental costs, effectiveness or cost-effectiveness of systemic therapies in breast cancer based on claims data: a systematic review. ISPOR conference; 2-6 november 2019; Kopenhagen.

Luyendijk M, **Visser O**, Blommestein HM, Uyl-de Groot C, **Siesling S**. Trends in survival and the introduction of novel systemic therapies for locoregional and metastatic breast cancer in the Netherlands, 1989-2017. SABCS, San Antonio Breast Cancer Group Symposium; 10-14 december 2019; San Antonio, Texas.

Noordhoek I, Bastiaannet E, van Eycken L, **Siesling S**, Walsh PM, Johannesen TB, Portielje JE, van de Velde CJ. International comparison of treatment and survival of older patients with primary metastatic breast cancer (PMBC): a population-based cohort study from the EURECCA Breast Cancer Group. ESSO, The European Society of Surgical Oncology Congress; 9-11 oktober 2019; Rotterdam.

Samiei S, van Nijnatten T, **de Munck L**, Keymeulen K, Simons JM, Kooreman L, **Siesling S**, Lobbes M, Smidt M. Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. SSO, Society of Surgical Oncology Annual Cancer Symposium; 27-30 maart 2019; San Diego, Californië.

Samiei S, van Kaathoven B, Boersma L, Granzier R, **Siesling S**, Engelen S, **de Munck L**, van Kuijk S, van der Hulst R, Lobbes M, van Nijnatten T, Smidt M. The risk of positive sentinel lymph node after neoadjuvant systemic therapy in clinically node negative breast cancer patients: implications of postmastectomy radiation therapy and immediate breast reconstruction. ESSO, The European Society of Surgical Oncology Congress; 9-11 oktober 2019; Rotterdam.

Samiei S, van Kaathoven B, Boersma L, Granzier R, **Siesling S**, Engelen S, **de Munck L**, van der Hulst R, Lobbes M, van Nijnatten T, Smidt M. The risk of positive sentinel lymph node after neoadjuvant systemic therapy in clinically node negative breast cancer patients: implications of postmastectomy radiation therapy and immediate breast reconstruction. SSO, Society of Surgical Oncology Annual Cancer Symposium; 27-30 maart 2019; San Diego, Californië.

Steenbruggen TG, van Ramshorst MS, van Werkhoven E, Dezentje VO, **Siesling S**, Linn SC, Sonke GS. The effect of adjuvant chemotherapy in small node-negative triple-negative breast cancer (TNBC). ASCO annual meeting; 31 mei-4 juni 2019; Chicago, Illinois.

van Maaren MC, Ortega Avila A, Bart J, Westenend PJ. Classic lobular carcinoma in situ in the Netherlands: a population-based analysis. SABCS, San Antonio Breast Cancer Group Symposium; 10-14 december 2019; San Antonio, Texas.

van Maaren MC, Hoveling LA, Hueting T, Strobbe LJ, Hendriks MP, Sonke GS, **Siesling S**. Validation of the online prediction model CancerMath in the Dutch breast cancer population. SABCS, San Antonio Breast Cancer Group Symposium; 10-14 december 2019; San Antonio, Texas.

van Nijnatten T, van Tiel L, **Voogd AC**, Groothuis-Oudshoorn K, **Siesling S**, Lobbes MB. Breast MRI affects overall survival, but not disease-free survival in breast cancer patients: a retrospective population-based study. ECR, European Congress of Radiology; 27 februari-3 maart 2019; Wenen.

van Steenhoven JE, Kuijer A, **Schreuder K**, Elias S, Diest PV, Wall EV, **Siesling S**, Dalen TV. The changing role of gene-expression profiling in the era of deescalating adjuvant chemotherapy in early stage breast cancer. ESMO, European Society for Medical Oncology Breast Cancer Congress; 2-4 mei 2019; Berlijn.

van Steenhoven JE, Kuijer A, Roos M, **Schreuder K**, Elias S, Diest PV, **Siesling S**, Smidt M, Dalen TV. The unintended beneficial side-effects of non-surgical treatment on the regional recurrence risk in breast cancer patients. SSO, Society of Surgical Oncology Annual Cancer Symposium; 27-30 maart 2019; San Diego, Californië.

Voelkel V, Draeger T, **Siesling S**, Groothuis-Oudshoorn C. INFLUENCE 2.0: a time-dependent model to predict locoregional recurrence and second primaries in early breast cancer patients. ISPOR conference; 2-6 november 2019; Kopenhagen.

Wolbers RG, Bode C, Siemerink EJ, **Siesling S**, Pieterse ME. Design of a Cognitive Bias Modification eHealth app to improve implicit vitality in breast cancer patients: a co-creation process. SABCS, San Antonio Breast Cancer Group Symposium; 10-14 december 2019; San Antonio, Texas.

Wolbers RG, Bode C, Pieterse ME, **Siesling S**, Siemerink EJ. Ontwerp van een Cognitive Bias Modification eHealth app om impliciet de vitaliteit van borstkanker patiënten te bevorderen: in een co-creation proces. ZGT Academie Wetenschapsdag; 16 oktober 2019; Almelo.

3 Bot-en wekedelentumoren

3.1 Publicaties met impactfactor

Goedhart LM, **Ho VK**, Dijkstra SP, Schreuder HW, Schaap GR, Ploegmakers JJ, van der Geest IC, van de Sande MA, Bramer JA, Suurmeijer AJ, Jutte PC. [Bone sarcoma incidence in the Netherlands](#). *Cancer Epidemiol.* 2019 Mar 20;60:31-38. doi: 10.1016/j.canep.2019.03.002. [Epub ahead of print]
Impactfactor: 2,619

Martin E, Coert JH, Flucke UE, Slooff WM, **Ho VK**, van der Graaf WT, van Dalen T, van de Sande MA, van Houdt WJ, Grünhagen DJ, Verhoef C. [A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours](#). *Eur J Cancer.* 2019 Nov 21;124:77-87. doi: 10.1016/j.ejca.2019.10.014. [Epub ahead of print]
Impactfactor: 6,680

Vos M, **Blaauwgeers HG**, **Ho VK**, van Houdt WJ, van der Hage JA, Been LB, Bonenkamp JJ, Bemelmans MH, van Dalen T, Haas RL, Grünhagen DJ, Verhoef C; Dutch Sarcoma Study Group (DSSG). [Increased survival of non low-grade and deep-seated soft tissue sarcoma after surgical management in high-volume hospitals: a nationwide study from the Netherlands](#). *Eur J Cancer.* 2019 Feb 15;110:98-106. doi: 10.1016/j.ejca.2019.01.005. [Epub ahead of print]
Impactfactor: 6,680

Weidema ME, Van de Geer E, Koelsche C, Desar I, Kemmeren P, Hillebrandt-Roeffen MH, **Ho VK**, Group P, van der Graaf WT, Versleijen-Jonkers YM, von Deimling A, Flucke UE. [DNA methylation profiling identifies distinct clusters in angiosarcomas](#). *Clin Cancer Res.* 2019 Sep 27. pii: clincanres.2180.2019. doi: 10.1158/1078-0432.CCR-19-2180. [Epub ahead of print]
Impactfactor: 8,911

Weidema ME, Flucke UE, van der Graaf WT, **Ho VK**, Hillebrandt-Roeffen MH; Dutch Nationwide Network and Registry of Histo- and Cytopathology (PALGA)-Group, Versleijen-Jonkers YM, Husson O, Desar IM. [Prognostic Factors in a Large Nationwide Cohort of Histologically Confirmed Primary and Secondary Angiosarcomas](#). *Cancers (Basel).* 2019 Nov 12;11(11). pii: E1780. doi: 10.3390/cancers11111780.
Impactfactor: 6,162

3.2 Presentaties en abstracts

Timbergen M, van der Graaf WT, Grünhagen DJ, Younger E, Sleijfer S, Dunlop A, Dean L, Verhoef C, **van de Pol-Franse LV**, Husson O. Health-related quality of life issues of patients affected by desmoid-type fibromatosis: experiences from two countries. ESSO, The European Society of Surgical Oncology Congress; 9-11 oktober 2019; Rotterdam.

4 Darmkanker

4.1 Publicaties met impactfactor

Arkenbosch JH, **van Erning FN**, Rutten HJ, Zimmerman D, de Wilt JH, **Beijer S**. The association between body mass index and postoperative complications, 30-day mortality and long-term survival in Dutch patients with colorectal cancer. *Eur J Surg Oncol*. 2019 Feb;45(2):160-166. doi: 10.1016/j.ejso.2018.09.012. Epub 2018 Oct 16.

Impactfactor: 3,379

Bonhof CS, van de Poll-Franse LV, Vissers PA, Wasowicz DK, Wegdam JA, Révész D, Vreugdenhil G, **Mols F**. Anxiety and depression mediate the association between chemotherapy-induced peripheral neuropathy and fatigue: Results from the population-based PROFILES registry. *Psychooncology*. 2019 Jul 10. doi: 10.1002/pon.5176. [Epub ahead of print]

Impactfactor: 3,43

Bos AC, Kortbeek D, **van Erning FN**, Zimmerman DD, **Lemmens VE**, Dekker JW, Maas HA. Postoperative mortality in elderly patients with colorectal cancer: The impact of age, time-trends and competing risks of dying. *Eur J Surg Oncol*. 2019 Apr 25. pii: S0748-7983(19)30412-3. doi: 10.1016/j.ejso.2019.04.020. [Epub ahead of print]

Impactfactor: 3,379

Bosch SL, **Verhoeven RH, Lemmens VE**, Simmer F, Poortmans P, de Wilt JH, Nagtegaal ID. Type of preoperative therapy and stage-specific survival after surgery for rectal cancer: a nationwide population-based cohort study. *Virchows Arch*. 2019 Aug 28. doi: 10.1007/s00428-019-02638-1. [Epub ahead of print]

Impactfactor: 2,868

Brouwer NP, Heil TC, Olde Rikkert MG, **Lemmens VE**, Rutten HJ, de Wilt JH, **van Erning FN**. The gap in postoperative outcome between older and younger patients with stage I-III colorectal cancer has been bridged; results from the Netherlands cancer registry. *Eur J Cancer*. 2019 Jun 1;116:1-9. doi: 10.1016/j.ejca.2019.04.036. [Epub ahead of print]

Impactfactor: 6,680

Brouwer NP, van der Kruijssen DE, Hugen N, de Hingh IH, Nagtegaal ID, **Verhoeven RH**, Koopman M, de Wilt JH. The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival. *Ann Surg Oncol*. 2019 Dec 2. doi: 10.1245/s10434-019-08100-5. [Epub ahead of print]

Impactfactor: 3,681

Claassen YH, Bastiaannet E, van Eycken E, Van Damme N, Martling A, Johansson R, Iversen LH, Ingeholm P, **Lemmens VE**, Liefers GJ, Holman FA, Dekker JW, Portielje JE, Rutten HJ, van de Velde CJ. Time trends of short-term mortality for octogenarians undergoing a colorectal resection in North Europe. *Eur J Surg Oncol*. 2019 Apr 9. pii: S0748-7983(19)30386-5. doi: 10.1016/j.ejso.2019.03.041. [Epub ahead of print]

Impactfactor: 3,379

de Gooyer JM, Verstegen MG, 't Lam-Boer J, Radema SA, **Verhoeven RH**, Verhoef C, Schreinemakers JM, de Wilt JH. Neoadjuvant Chemotherapy for Locally Advanced T4 Colon Cancer: A Nationwide Propensity-Score Matched Cohort Analysis. *Dig Surg*. 2019 Oct 29:1-10. doi: 10.1159/000503446. [Epub ahead of print]

Impactfactor: 1,884

Detering R, de Neree Tot Babberich MP, **Bos AC**, Dekker JW, Wouters MW, Bemelman WA, Beets-Tan RG, Marijnen CA, Hompes R, Tanis PJ; Dutch ColoRectal Audit Group. Nationwide analysis of hospital variation in preoperative radiotherapy use for rectal cancer following guideline revision. *Eur J Surg Oncol*. 2019 Dec 20. pii: S0748-7983(19)31509-4. doi: 10.1016/j.ejso.2019.12.016. [Epub ahead of print]

Impactfactor: 3,379

Giesen LJ, **van Erning FN**, **Vissers PA**, Maas HA, Rutten HJ, **Lemmens VE**, Dekker JW. Inter-hospital variation in resection rates of colon cancer in the Netherlands: A nationwide study. *Eur J Surg Oncol*. 2019 Jun 8. pii: S0748-7983(19)30506-2. doi: 10.1016/j.ejso.2019.06.012. [Epub ahead of print]
Impactfactor: 3,379

Jongeneel G, Klausch T, **van Erning FN**, **Vink GR**, Koopman M, Punt C, Greuter M, Coupé V. Estimating adjuvant treatment effects in stage II colon cancer: comparing the synthesis of randomized clinical trial data to real world data. *Int J Cancer*. 2019 Aug 19. doi: 10.1002/ijc.32629. [Epub ahead of print]
Impactfactor: 4,982

Klaver CE, Wisselink DD, Punt CJ, Snaebjornsson P, Crezee J, Aalbers AG, Brandt A, Bremers AJ, Burger JW, Fabry HF, Ferenschild F, Festen S, van Grevenstein WM, Hemmer PH, de Hingh IH, Kok NF, Musters GD, Schoonderwoerd L, Tuynman JB, van de Ven AW, van Westreenen HL, Wiezer MJ, Zimmerman DD, van Zweeden AA, Dijkgraaf MG, Tanis PJ; COLOPEC collaborators group (**Mol L**). Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. *Lancet Gastroenterol Hepatol*. 2019 Oct;4(10):761-770. doi: 10.1016/S2468-1253(19)30239-0. Epub 2019 Jul 29.
Impactfactor: 12,856

Kwakman JJ, van Werkhoven E, Simkens LHJ, van Rooijen JM, van de Wouw YA, Tije AJ, Creemers GM, Hendriks MP, Los M, van Alphen RJ, Polée MB, Muller EW, van der Velden AM, van Voorthuizen T, Koopman M, **Mol L**, Punt CJ. Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group. *Clin Colorectal Cancer*. 2019 Jan 29. pii: S1533-0028(18)30531-0. doi: 10.1016/j.clcc.2019.01.002. [Epub ahead of print] No abstract available.
Impactfactor: 3,176

Legué LM, **van Erning FN**, Bernards N, **Lemmens VE**, **de Hingh IH**, Creemers GJ. Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study. *Target Oncol*. 2019 Oct 17. doi: 10.1007/s11523-019-00681-1. [Epub ahead of print]
Impactfactor: 3,683

Legué LM, Bernards N, **Lemmens VE**, **de Hingh IH**, Creemers GJ, **van Erning FN**. Palliative chemotherapy for patients with synchronous metastases of small-bowel adenocarcinoma: a reflection of daily practice. *United European Gastroenterology Journal* 2019 Jun: pp. 1380-1388.
Impactfactor: 3,453

Legué LM, **van Erning FN**, Creemers GJ, **de Hingh IH**, **Lemmens VE**, Huysentruyt CJ. The prognostic relevance of histologic subtype in appendiceal adenocarcinoma. *Eur J Surg Oncol*. 2019 Oct 15. pii: S0748-7983(19)30898-4. doi: 10.1016/j.ejso.2019.10.018. [Epub ahead of print]
Impactfactor: 3,379

Madani A, Kuijpers CC, Sluijter CE, Von der Thüsen JH, Grünberg K, **Lemmens VE**, Overbeek LI, Nagtegaal ID. Decrease of variation in the grading of dysplasia in colorectal adenomas with a national e-learning module. *Histopathology*. 2019 Feb 6. doi: 10.1111/his.13834. [Epub ahead of print]
Impactfactor: 3,294

Mazzotti F, Cucchetti A, Claassen YH, **Bos AC**, Bastiaannet E, Ercolani G, Dekker JW. Years of Life Lost for Older Patients After Colorectal Cancer Diagnosis. *World J Surg*. 2019 Mar 12. doi: 10.1007/s00268-019-04978-0. [Epub ahead of print]
Impactfactor: 2,768

Ramsey I, **de Rooij BH**, **Mols F**, Corsini N, **Horevoorts NJ**, Eckert M, **van de Poll-Franse LV**. Cancer survivors who fully participate in the PROFILES registry have better health-related quality of life than those who drop out. *J Cancer Surviv*. 2019 Sep 6. doi: 10.1007/s11764-019-00793-7. [Epub ahead of print]
Impactfactor: 3,585

Ramsey I, **de Rooij BH**, **Mols F**, Corsini N, **Horevoorts NJ**, Eckert M, **van de Poll-Franse LV**. Correction to: Cancer survivors who fully participate in the PROFILES registry have better health-related quality of life than those who drop out. *J Cancer Surviv*. 2019 Nov 21. doi: 10.1007/s11764-019-00813-6. [Epub ahead of print]
Impactfactor: 3,585

Rombouts AJ, Hugen N, **Elferink MA**, Poortmans PM, Nagtegaal ID, de Wilt JH. Increased risk for second primary rectal cancer after pelvic radiation therapy. *Eur J Cancer*. 2019 Nov 22;124:142-151. doi: 10.1016/j.ejca.2019.10.022. [Epub ahead of print]
Impactfactor: 6,680

Rombouts AJ, Hugen N, **Verhoeven RH**, Kuiper JG, Poortmans PM, de Wilt JH, Nagtegaal ID. Is preoperative chemoradiation in rectal cancer patients modulated by ACE inhibitors? Results from the Dutch Cancer Registry. *Radiother Oncol*. 2019 Jun 25;138:86-92. doi: 10.1016/j.radonc.2019.06.010. [Epub ahead of print]
Impactfactor: 5,252

Rovers KP, Bakkers C, Simkens GA, Burger JW, Nienhuijs SW, Creemers GM, Thijs AM, Brandt-Kerkhof AR, Madsen EV, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HM, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar EC, Los M, Hunting CB, Aalbers AG, Kok NF, Kuhlmann KF, Boot H, Chalabi M, Kruijff S, Been LB, van Ginkel RJ, de Groot DJ, Fehrmann RS, de Wilt JH, Bremers AJ, de Reuver PR, Radema SA, Herbschleb KH, van Grevenstein WM, Witkamp AJ, Koopman M, Haj Mohammad N, van Duyn EB, Mastboom WJ, Mekenkamp LJ, Nederend J, Lahaye MJ, Snaebjornsson P, Verhoef C, van Laarhoven HW, Zwinderman AH, **Bouma JM**, Kranenburg O, van 't Erve I, Fijneman RJ, Dijkgraaf MG, Hemmer PH, Punt CJ, Tanis PJ, de Hingh IH; Dutch Peritoneal Oncology Group (DPOG); Dutch Colorectal Cancer Group (DCCG). Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). *BMC Cancer*. 2019 Apr 25;19(1):390. doi: 10.1186/s12885-019-5545-0.
Impactfactor: 2,933

Souwer ET, **Oerlemans S**, **van de Poll-Franse LV**, **van Erning FN**, van den Bos F, Schuijtemaker JS, van den Berkmortel FW, Ten Bokkel Huinink D, Hamaker ME, Dekker JW, Wientjes CA, Portielje JE, Maas HA. The impact of colorectal surgery on health-related quality of life in older functionally dependent patients with cancer - A longitudinal follow-up study. *J Geriatr Oncol*. 2019 May 7. pii: S1879-4068(18)30478-8. doi: 10.1016/j.jgo.2019.04.013. [Epub ahead of print]
Impactfactor: 3,164

van der Hout A, Neijenhuijs KI, Jansen F, van Uden-Kraan CF, Aaronson NK, Groenvold M, Holzner B, Terwee CB, **van de Poll-Franse LV**, Cuijpers P, Verdonck-de Leeuw IM. Measuring health-related quality of life in colorectal cancer patients: systematic review of measurement properties of the EORTC QLQ-CR29. *Support Care Cancer*. 2019 Apr 13. doi: 10.1007/s00520-019-04764-7. [Epub ahead of print] Review.
Impactfactor: 2,754

van Rooijen SJ, Molenaar CJ, Schep G, van Lieshout RH, **Beijer S**, Dubbers R, Rademakers N, Papen-Botterhuis NE, van Kempen S, Carli F, Roumen RM, Slooter GD. Making patients fit for surgery: introducing a four pillar multimodal prehabilitation program in colorectal cancer. *Am J Phys Med Rehabil*. 2019 May 13. doi: 10.1097/PHM.0000000000001221. [Epub ahead of print]
Impactfactor: 1,908

van Rooijen SJ, Carli F, Dalton S, Thomas G, Bojesen R, Le Guen M, Barizien N, Awasthi R, Minnella E, **Beijer S**, Martínez-Palli G, van Lieshout R, Gögenur I, Feo C, Johansen C, Scheede-Bergdahl C, Roumen R, Schep G, Slooter G. Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation. *BMC Cancer*. 2019 Jan 22;19(1):98. doi: 10.1186/s12885-018-5232-6.
Impactfactor: 2,933

van Veen MR, Mols F, Bours MJ, Weijnenberg MP, Kampman E, Beijer S. Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations for cancer prevention is associated with better health-related quality of life among long-term colorectal cancer survivors: results of the PROFILES registry. *Support Care Cancer*. 2019 Mar 29. doi: 10.1007/s00520-019-04735-y. [Epub ahead of print]
Impactfactor: 2,754

van Veen MR, Mols F, Smeets L, Kampman E, Beijer S. Colorectal cancer survivors' beliefs on nutrition and cancer; correlates with nutritional information provision. *Support Care Cancer*. 2019 Jun 21. doi: 10.1007/s00520-019-04934-7. [Epub ahead of print]
Impactfactor: 2,754

Verseveld M, de Wilt JH, Elferink MA, de Graaf EJ, Verhoef C, Pouwels S, Doornebosch PG. Survival after local excision for rectal cancer: a population-based overview of clinical practice and outcome. *Acta Oncol*. 2019 May 20:1-4. doi: 10.1080/0284186X.2019.1616816. [Epub ahead of print] No abstract available.
Impactfactor: 3,298

4.2 Overige publicaties

Sluijter CE, van Workum F, Wiggers T, van de Water C, Visser O, van Slooten HJ, Overbeek LI, Nagtegaal ID. Improvement of Care in Patients With Colorectal Cancer: Influence of the Introduction of Standardized Structured Reporting for Pathology. *JCO Clin Cancer Inform*. 2019 May;3:1-12. doi: 10.1200/CCI.18.00104.

4.3 Posters

Winkels RM, van Baar H, Beijer S, Kampman E. Are skeletal muscle mass and density associated with fatigue in early-stage colorectal cancer patients? ASPO, American Society of Preventive Oncology Annual Conference; 10-12 maart 2019; Tampa, Florida.

4.4 Presentaties en abstracts

Hamers P, Bos AC, May A, Punt CJ, Koopman M, Vink GR. Recent changes in overall survival of real-life stage IV colorectal cancer patients. ASCO, American Society of Clinical Oncology Annual Meeting; 31 mei-4 juni 2019; Chicago.

Kwakman JJ, van Werkhoven E, Simkens LH, van Rooijen JM, van der Wouw A, ten Tije AJ, Creemers GJ, Hendriks MP, Los M, van Alphen R, Polee MB, Muller EW, van der Velden A, van Voorthuizen T, Koopman M, Mol L, Punt CJ. Updated survival analysis of the randomized phase III trial comparing S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (SALTO) by the Dutch colorectal cancer group. ESMO, World Congress on Gastrointestinal Cancer; 27 september-1 oktober 2019; Barcelona.

Rombouts AJ, Hugen N, Verhoeven RH, Kuiper JG, Poortmans PM, de Wilt HJ, Nagtegaal ID. Can we modulate response to preoperative therapy in rectal cancer patients by ACE inhibitors? International Conference on Pharmacoepidemiology & therapeutic risk management; 24-28 augustus 2019; Philadelphia.

5 Gynaecologische tumoren

5.1 Publicaties met impactfactor

Bielska-Lasota M, Rossi S, Krzyżak M, Haelens A, Domenic A, De Angelis R, Maciejczyk A, Rodríguez-Barranco M, Zadnik V, Minicozzi P; EUROCARE-5 Working Group (**Visser O, Otter R, Aarts MJ**). Reasons for low cervical cancer survival in new accession European Union countries: a EUROCARE-5 study. *Arch Gynecol Obstet*. 2019 Dec 18. doi: 10.1007/s00404-019-05412-5. [Epub ahead of print] Impactfactor: 2,199

de Lange NM, **Ezendam NP**, Kwon JS, Vandenput I, Mirchandani D, Amant F, van der Putten LJ, Pijnenborg JM. Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer. *Curr Oncol*. 2019 Apr;26(2):e226-e232. doi: 10.3747/co.26.4655. Epub 2019 Apr 1. Impactfactor: 1,862

Elzakkars JC, **van der Aa MA**, van Altena AM, de Hullu JA, Harmsen MG. Further insights into the role of tumour characteristics in survival of young women with epithelial ovarian cancer. *Gynecol Oncol*. 2019 Aug 30. pii: S0090-8258(19)31470-2. doi: 10.1016/j.ygyno.2019.08.018. [Epub ahead of print] Impactfactor: 4,393

Schuurman MS, Timmermans M, van Gorp T, de Vijver KK, Kruitwagen RF, **Lemmens VE, van der Aa MA**. Trends in incidence, treatment and survival of borderline ovarian tumors in the Netherlands: a nationwide analysis. *Acta Oncol*. 2019 May 28;1-7. doi: 10.1080/0284186X.2019.1619935. [Epub ahead of print] Impactfactor: 3,298

Timmermans M, Sonke GS, Van de Vijver KK, Ottevanger PB, Nijman HW, **van der Aa MA**, Kruitwagen RFP. Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer. *Int J Gynecol Cancer*. 2019 Jan 21. pii: ijgc-2018-000100. doi: 10.1136/ijgc-2018-000100. [Epub ahead of print] Impactfactor: 1,746

Timmermans M, Sonke GS, Slangen BF, Baalbergen A, Bekkers RL, Fons G, Gerestein CG, Kruse AJ, Roes EM, Zusterzeel PL, Van de Vijver KK, Kruitwagen RF, **van der Aa MA**. Outcome of surgery in advanced ovarian cancer varies between geographical regions; opportunities for improvement in The Netherlands. *Eur J Surg Oncol*. 2019 Apr 12. pii: S0748-7983(19)30401-9. doi: 10.1016/j.ejso.2019.04.009. [Epub ahead of print] Impactfactor: 3,379

Timmermans M, Zwakman N, Sonke GS, Van de Vijver KK, Duk MJ, **van der Aa MA**, Kruitwagen RF. Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer. *Eur J Obstet Gynecol Reprod Biol*. 2019 Jul 26;240:364-369. doi: 10.1016/j.ejogrb.2019.07.010. [Epub ahead of print] Impactfactor: 2,024

Timmermans M, van der Hel O, Sonke GS, Van de Vijver KK, **van der Aa MA**, Kruitwagen RF. The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review. *Gynecol Oncol*. 2019 Feb 27. pii: S0090-8258(19)30129-5. doi: 10.1016/j.ygyno.2019.02.019. [Epub ahead of print] Review. Impactfactor: 4,393

van Baal JO, Van de Vijver KK, Algera MD, **van der Aa MA**, Sonke GS, van Driel WJ, Kenter GG, Amant FC, Lok CA. The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer. *Gynecol Oncol*. 2019 Apr 1. pii: S0090-8258(19)30492-5. doi: 10.1016/j.ygyno.2019.03.257. [Epub ahead of print] Impactfactor: 4,393

van der Hel OL, Timmermans M, van Altena AM, Kruitwagen RF, Slangen BF, Sonke GS, van de Vijver KK, **van der Aa MA**. Overview of non-epithelial ovarian tumours: Incidence and survival in the Netherlands, 1989-2015. *Eur J Cancer*. 2019 Jul 18;118:97-104. doi: 10.1016/j.ejca.2019.06.005. [Epub ahead of print]
Impactfactor: 6,680

van Walree IC, Hamaker ME, **van de Poll-Franse LV**, Vos MC, Boll D, van Huis-Tanja LH, **Ezendam NP**. Older ovarian cancer survivors report lower long-term health-related quality of life than younger survivors: A study from the population-based profiles registry. *Gynecol Oncol*. 2019 Feb 13. pii: S0090-8258(19)30104-0. doi: 10.1016/j.ygyno.2019.02.001. [Epub ahead of print]
Impactfactor: 4,393

Zandbergen N, de Rooij BH, Vos MC, Pijnenborg JMA, Boll D, Kruitwagen RF, **van de Poll-Franse LV, Ezendam NP**. Changes in health-related quality of life among gynecologic cancer survivors during the two years after initial treatment: a longitudinal analysis. *Acta Oncol*. 2019 Jan 30:1-11. doi: 10.1080/0284186X.2018.1560498. [Epub ahead of print]
Impactfactor: 3,298

Zijlstra M, Timmermans M, Fransen H, van der Aa MA, Reyners A, **Raijmakers N, van de Poll-Franse LV**. Treatment patterns and associated factors in patients with advanced epithelial ovarian cancer: a population-based study. *Int J Gynecol Cancer*. 2019 Jul;29(6):1032-1037. doi: 10.1136/ijgc-2019-000489. Impactfactor: 1,746

5.2 Proefschriften en promoties

Timmermans M. Optimising patient selection to improve outcome in advanced ovarian cancer. Maastricht: Universiteit Maastricht; 30 augustus 2019. Promotoren: RF Kruitwagen, KK van de Vijver. Copromotoren: **MA van der Aa**, GS Sonke. Beoordelingscommissie: CH Dejong, F Amant, M de Boer, **VE Lemmens**, EJ Speel.

5.3 Posters

de Rooij BH, Ezendam NP, Vos C, Pijnenborg JM, Boll, D, Kruitwagen RF, **van de Poll-Franse LV**. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. *Cancer Survivorship Conference*; 28-29 maart 2019; Sydney.

de Rooij BH, Skorstad M, Moustgaard Jeppesen M, Holm Bergholdt S, **Ezendam NP**, Jensen PT, Vistad I, **van de Poll-Franse LV**. Wide variation in self-management skills in gynaecological cancer survivors from the Netherlands, Denmark and Norway: first results of the InCHARGE study. *ESGO, European Congress on Gynaecological Oncology*; 2-5 november 2019; Athene.

Ezendam NP, de Rooij BH, Creutzberg CL, Kruitwagen RF, van Lonkhuijzen LR, Apperloo MJ, Gerestein K, Baalbergen A, Boll D, Vos MC, **van de Poll-Franse LV**. Effect of a reduced follow-up schedule on patient satisfaction with care among early stage endometrial cancer patients: one-year preliminary results of the ENSURE randomized controlled trial. *ESGO, European Congress on Gynaecological Oncology*; 2-5 november 2019; Athene.

5.4 Presentaties en abstracts

de Rooij BH, Ezendam NP, Vos C, Pijnenborg JM, Boll, D, Kruitwagen RF, **van de Poll-Franse LV**. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. *Cancer Survivorship Conference*; 28-29 maart 2019; Sydney.

de Rooij BH, Skorstad M, Moustgaard Jeppesen M, Holm Bergholdt S, **Ezendam NP**, Jensen PT, Vistad I, **van de Poll-Franse LV**. Wide variation in self-management skills in gynaecological cancer survivors from the Netherlands, Denmark and Norway: first results of the InCHARGE study. *ESGO, European Congress on Gynaecological Oncology*; 2-5 november 2019; Athene.

Ezendam NP. How to measure consequences of cancer treatment and patients needs? *ISPOG, International Society of Psychosomatic Obstetrics and gynaecology*; 9-12 oktober 2019; Den Haag.

Poort H, **de Rooij BH**, Weng S, **Ezendam NP**, **van de Poll-Franse LV**, Wright AA. Predictors and trajectories of fatigue in ovarian and uterine cancer. ASCO, American Society of Clinical Oncology Annual Meeting; 31 mei-4 juni 2019; Chicago.

van de Poll-Franse LV. Long-term sequelae of gynaecological cancer. ISPOG, International Society of Psychosomatic Obstetrics and gynaecology; 9-12 oktober 2019; Den Haag.

van der Hel OL, **Timmermans M**, van Altena AM, Kruitwagen RF, Slangen BF, Sonke GS, van de Vijver KK, **van der Aa MA**. Overview of non-epithelial ovarian tumours: incidence and survival in the Netherlands. ESGO, European Congress on Gynaecological Oncology; 2-5 november 2019; Athene.

van Weelden WJ, Reijnen C, Eggink F, de Lange N, Nijman H, Boll D, **van der Aa MA**, Pijnenborg J. Impact of different adjuvant treatment strategies on survival in stage III endometrial cancer: a population-based study. ESGO, European Congress on Gynaecological Oncology; 2-5 november 2019; Athene.

Vos M, Graafsma I, Boll D, **van de Poll-Franse LV**, **Ezendam NP**. Changes in sexuality in ovarian cancer survivors and their partners: a cross-sectional study from the PROFILES registry. ISSWSH/ISSM Joint Meeting; 7-10 maart 2019; Atlanta.

Wenzel H, Bekkers R, **Lemmens VE**, Nijman H, **van der Aa MA**. Guideline adherence and survival in locally advanced cervical cancer in the Netherlands between 2009-2016. ESGO, European Congress on Gynaecological Oncology; 2-5 november 2019; Athene.

Wenzel H, van Gorp T, Bekkers R, de Kroon C, van Lonkhuijzen LR, Massuger L, Nijman H, Smolders R, van Trommel N, Yigit R, Zweemer R, Kruitwagen RF, **van der Aa MA**. Predictors of short-term surgical complications after radical hysterectomy for early-stage cervical cancer. ESGO, European Congress on Gynaecological Oncology; 2-5 november 2019; Athene.

Wenzel H, Smolders R, Beltman J, Lambrechts S, Trum H, Yigit R, Zusterzeel P, Zweemer R, Bekkers R, **van der Aa MA**. Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy in the Netherlands. ESGO, European Congress on Gynaecological Oncology; 2-5 november 2019; Athene.

6 Hemato-oncologie

6.1 Publicaties met impactfactor

Blommestein HM, van Beurden-Tan CH, Franken MG, Uyl-de Groot CA, Sonneveld P, Zweegman S. Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. *Haematologica*. 2019 May;104(5):1026-1035. doi: 10.3324/haematol.2018.206912. Epub 2019 Jan 3. Impactfactor: 7,570

Dinmohamed AG, Visser O. Incidence of acute promyelocytic leukemia across Europe: results of RARECAREnet-a population-based study. *Stem Cell Investig*. 2019 Nov 26;6:37. doi: 10.21037/sci.2019.10.03. eCollection 2019. Impactfactor: 4,806

Posthuma HL, Zijlstra JM, **Visser O**, Lugtenburg PJ, Kersten MJ, **Dinmohamed AG**. Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993-2016. *Br J Haematol*. 2019 Nov 4. doi: 10.1111/bjh.16290. [Epub ahead of print] Impactfactor: 5,206

Servadio M, Cottone F, Sommer K, **Oerlemans S, van de Poll-Franse LV**, Efficace F. Physical activity and health-related quality of life in multiple myeloma survivors: the PROFILES registry. *BMJ Support Palliat Care*. 2019 Jun 28. pii: bmjpcare-2018-001755. doi: 10.1136/bmjpcare-2018-001755. [Epub ahead of print] Impactfactor: 3,208

6.2 Posters

Brink M, Minnema C, **Visser O**, Broijl A, van de Donk NW, Sonneveld P, Zweegman S, **Dinmohamed AG**. The impact of a prior malignancy on the development of a subsequent malignancy in multiple myeloma revisited: a competing risk analysis. EHA, European Hematology Association Congres; 13-16 juni 2019; Amsterdam.

Dinmohamed AG, Visser O. Survival disparities in hairy cell leukemia across Europe: results of rarecarenet: a population-based study. EHA, European Hematology Association Congres; 13-16 juni 2019; Amsterdam.

Dinnessen M, van der Poel M, Tonino S, **Visser O**, Blijlevens N, Kersten MJ, Lugtenburg P, **Dinmohamed AG**. Primary therapy and survival of follicular lymphoma in the Netherlands: a population-based analysis among 12,008 patients diagnosed from 1989-2016. EHA, European Hematology Association Congres; 13-16 juni 2019; Amsterdam.

Dinnessen M, **Visser O**, Tonino S, van der Poel M, Blijlevens N, Kersten MJ, Lugtenburg P, **Dinmohamed AG**. The impact of prior malignancies on the development of second malignancies and survival in patients with follicular lymphoma: a nationwide population-based study in the Netherlands. EHA, European Hematology Association Congres; 13-16 juni 2019; Amsterdam.

Driessen J, **Visser O**, Zijlstra JM, Lugtenburg PJ, Kersten MJ, **Dinmohamed AG**. Primary therapy and relative survival in classic Hodgkin lymphoma: a nationwide population-based study among 9,367 adult patients diagnosed in the Netherlands from 1989 to 2016. EHA, European Hematology Association Congres; 13-16 juni 2019; Amsterdam.

Durmaz M, Issa DE, **Visser O**, Blijlevens N, Zweegman S, Kersten MJ, Lugtenburg PJ, Chamuleau ME, **Dinmohamed AG**. Survival continues to increase in diffuse large B-cell lymphoma: a population-based analysis among 25,143 patients diagnosed in the Netherlands between 1989 and 2016. EHA, European Hematology Association Congres; 13-16 juni 2019; Amsterdam.

Ector G, **Visser O**, Westerweel P, Janssen J, Blijlevens N, **Dinmohamed AG**. Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands 1989-2016. EHA, European Hematology Association Congress; 13-16 juni 2019; Amsterdam.

Issa D, **Dinmohamed AG**, Wondergem M, Blommestein H, **Huijgens PC**, Lugtenburg P, **Visser O**, Zweegman S, Chamuleau M. Population-based study on different regimens of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma in the Netherlands supports the use of 6 cycles of R-CHOP21. EHA, European Hematology Association Congress; 13-16 juni 2019; Amsterdam.

Issa D, **Dinmohamed AG**, Wondergem M, Blommestein H, **Huijgens PC**, Lugtenburg P, **Visser O**, Zweegman S, Chamuleau M. Population-based study on different regimens of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma in the Netherlands supports the use of 6 cycles of R-CHOP21. ICML, International Conference on Malignant Lymphoma; 18-22 juni 2019; Lugano.

Posthuma HL, Zijlstra JM, **Visser O**, Lugtenburg PJ, Kersten MJ, **Dinmohamed AG**. Primary therapy and survival among adult patients with nodular lymphocyte predominant Hodgkin lymphoma (NLPHL): a population-based analysis in the Netherlands, 1993-2016. EHA, European Hematology Association Congress; 13-16 juni 2019; Amsterdam.

Servadio M, Cottone F, Sommer K, **Oerlemans S, van de Poll-Franse LV**, Efficace F. Physical activity and health-related quality of life outcomes in multiple myeloma survivors: results from the Profiles registry. Italian Society of Hematology Congress; 7-9 oktober 2019; Rome.

van Lieshout R, Tick LW, Dieleman JP, Custers S, van Dongen MS, van der Lee D, Schaaphok AR, Snellen M, Schouten HC, **Beijer S**. Changes in body weight and serum liver tests associated with parenteral-versus no parenteral nutrition in acute myeloid leukemia patients during remission induction treatment. ESPEN Congress; 31 augustus-3 september 2019; Krakow.

van der Straten L, Levin M, **Visser O**, Posthuma EF, Doorduijn JK, Kater AP, **Dinmohamed AG**. Survival continues to increase in chronic lymphocytic leukemia: a population-based analysis among 20,324 patients diagnosed in the Netherlands between 1989 and 2015. ICML, International Conference on Malignant Lymphoma; 18-22 juni 2019; Lugano.

6.3 Presentaties en abstracts

Brink M, Visser O, Zweegman S, Sonneveld P, Broijl A, van de Donk N, **Dinmohamed AG**. Treatment and survival of patients with primary plasma cell leukemia in the Netherlands. DHC, Dutch Hematology Congress; 23-25 januari 2019; Arnhem.

Rier HN, Kharagjitsing H, van Rosmalen J, van Vugt J, Westerweel PE, de Jongh E, **Dinmohamed AG**, Doorduijn J, Kock M, Levin M. Prognostic impact of low muscle mass and muscle density in patients with diffuse large B-cell lymphoma. SIOG, Society of Geriatric Oncology Annual Conference; 14-16 november 2019; Genève.

Slot S, **Visser O**, Schaap N, Janssen J, te Boekhorst P, Zweegman S, **Dinmohamed AG**. Population-based outcomes in pMF. DHC, Dutch Hematology Congress; 23-25 januari 2019; Arnhem.

van der Straten L, Levin MD, **Visser O**, Posthuma E, Doorduijn J, Kater A, **Dinmohamed AG**. Survival of CLL in the Netherlands. DHC, Dutch Hematology Congress; 23-25 januari 2019; Arnhem.

van Lieshout R, Tick LW, Dieleman JP, Custers S, van der Lee D, van Dongen MS, Schaaphok AR, Snellen M, Schouten HC, **Beijer S**. Body weight changes and hepatobiliary effects associated with parenteral nutrition in patients with acute myeloid leukemia during remission induction treatment. ESPEN Congress; 31 augustus-3 september 2019; Krakow.

7 Hoofdhalskanker

7.1 Publicaties met impactfactor

Boeve K, Melchers LJ, Schuurung E, Roodenburg JL, Halmos GB, **van Dijk BA**, van der Vegt B, Witjes MJ. Addition of tumor infiltration depth and extranodal extension improves the prognostic value of the pathological TNM classification for early stage oral squamous cell carcinoma. *Histopathology*. 2019 Apr 25. doi: 10.1111/his.13886. [Epub ahead of print]
Impactfactor: 3,294

Plaat RE, **van Dijk BA**, Muller Kobold AC, Steenbakkens RJ, Links TP, van der Laan BF, Plaat BE. Onset of hypothyroidism after total laryngectomy: Effects of thyroid gland surgery and preoperative and postoperative radiotherapy. *Head Neck*. 2019 Dec 13. doi: 10.1002/hed.26048. [Epub ahead of print]
Impactfactor: 2,442

Trama A, Botta L, Foschi R, **Visser O**, Borrás JM, Žagar T, Primic-Žakelj M, Bella F, Dimitrova N, Gatta G, Licitra L on behalf of the RARECAREnet High Resolution Working Group. Quality of Care Indicators for Head and Neck Cancers: The Experience of the European Project RARECAREnet. *Front. Oncol.*, 28 August 2019 | <https://doi.org/10.3389/fonc.2019.00837>
Impactfactor: 4,137

van de Ven SE, Derikx LA, Nagtegaal ID, van Herpen CM, Takes RP, Melchers WJ, Pierik M, van den Heuvel T, **Verhoeven RH**, Hoentjen F, Nissen LH. Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors. *Inflamm Bowel Dis*. 2019 Sep 27. pii: izz210. doi: 10.1093/ibd/izz210. [Epub ahead of print]
Impactfactor: 4,005

8 Huidkanker

8.1 Publicaties met impactfactor

Arts LP, Waalboer-Spuij R, de Roos KP, Thissen MR, Scheijmans LJ, **Aarts MJ**, **Oerlemans S**, Lybeert ML, **Louwman MW**. Health-Related Quality of Life, Satisfaction with Care, and Cosmetic Results in Relation to Treatment among Patients with Keratinocyte Cancer in the Head and Neck Area: Results from the PROFILES Registry. *Dermatology*. 2019 Aug 21:1-10. doi: 10.1159/000502033. [Epub ahead of print] Impactfactor: 2,497

Deckers EA, **Hoekstra-Weebers JE**, Damude S, Francken AB, Ter Meulen S, Bastiaannet E, Hoekstra HJ. The MELFO Study: A Multicenter, Prospective, Randomized Clinical Trial on the Effects of a Reduced Stage-Adjusted Follow-Up Schedule on Cutaneous Melanoma IB-IIC Patients-Results After 3 Years. *Ann Surg Oncol*. 2019 Sep 18. doi: 10.1245/s10434-019-07825-7. [Epub ahead of print] Impactfactor: 3,681

El Sharouni MA, Witkamp AJ, Sigurdsson V, van Diest PJ, **Louwman MW**, Kukutsch NA. Sex matters: men with melanoma have a worse prognosis than women. *J Eur Acad Dermatol Venereol*. 2019 Jun 27. doi: 10.1111/jdv.15760. [Epub ahead of print] Impactfactor: 5,113

Jochems A, van der Kooij MK, Fiocco M, Schouwenburg MG, Aarts MJ, van Akkooi AC, van den Berkmortel FW, Blank CU, van den Eertwegh AJ, Franken MG, de Groot JB, Haanen JB, Hospers GA, Koorstra RH, Kruit WH, **Louwman MW**, Piersma D, van Rijn RS, Suijkerbuijk KP, Ten Tije AJ, Vreugdenhil G, Wouters MW, van Zeijl MC, van der Hoeven KJ, Kapiteijn E. Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry. *Cancers (Basel)*. 2019 Jul 18;11(7). pii: E1007. doi: 10.3390/cancers11071007. Impactfactor: 6,162

Lee CB, Kan WC, Gran S, Mooyaart A, Mureau MA, Williams HC, Matin R, van den Bos R, **Hollestein LM**. Dermatofibrosarcoma Protuberans Re-excision and Recurrence Rates in the Netherlands Between 1989 and 2016. *Acta Derm Venereol*. 2019 Aug 13. doi: 10.2340/00015555-3287. [Epub ahead of print] Impactfactor: 3,531

Leeneman B, Franken MG, Coupé VM, Hendriks MP, Kruit W, Plaisier PW, van Ruth S, Verstijnen JA, Wouters MW, **Blommestein HM**, Uyl-de Groot CA. Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. *Eur J Surg Oncol*. 2019 Feb 5. pii: S0748-7983(19)30269-0. doi: 10.1016/j.ejso.2019.01.225. [Epub ahead of print] Impactfactor: 3,379

Noels EC, **Hollestein LM**, van Egmond S, Lugtenberg M, van Nistelrooij LPJ, Bindels P, van der Lei J, Stern RS, Nijsten T, Wakkee M. Healthcare utilization and management of actinic keratosis in primary and secondary care: a complementary database analysis. *Br J Dermatol*. 2019 Jan 12. doi: 10.1111/bjd.17632. [Epub ahead of print] Impactfactor: 6,714

Schuurman MS, **Hollestein LM**, Bastiaannet E, **Posthuma EF**, van Akkooi AJ, Kukutsch NA, Aarts MJ, Wakkee M, **Lemmens VE**, **Louwman MW**. Melanoma in older patients: declining gap in survival between younger and older patients with melanoma. *Acta Oncol*. 2019 Jul 26:1-9. doi: 10.1080/0284186X.2019.1643914. [Epub ahead of print] Impactfactor: 3,298

Sondermeijer L, Lamboo LG, de Waal AC, Galesloot TE, Kiemeny LA, van Rossum M, **Aben KK**. Cigarette Smoking and the Risk of Cutaneous Melanoma: A Case-Control Study. *Dermatology*. 2019 Sep 10:1-9. doi: 10.1159/000502129. [Epub ahead of print] Impactfactor: 2,497

Uitentuis SE, **Louwman MW**, van Akkooi AC, Bekkenk M. Treatment and survival of Merkel cell carcinoma since 1993: a population-based cohort study in the Netherlands. *J Am Acad Dermatol*. 2019 Jan 28. pii: S0190-9622(19)30149-5. doi: 10.1016/j.jaad.2019.01.042. [Epub ahead of print]
Impactfactor: 7,102

Verver D, van der Veldt A, van Akkooi A, Verhoef C, Grünhagen DJ, **Louwman MW**. Reply to: The real-world outcome of metastatic melanoma: unknown primary versus known cutaneous. *Int J Cancer*. 2019 Aug 19. doi: 10.1002/ijc.32630. [Epub ahead of print] No abstract available.
Impactfactor: 4,982

Verver D, van der Veldt A, van Akkooi A, Verhoef C, Grünhagen DJ, **Louwman WJ**. Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: a Dutch population-based study. *Int J Cancer*. 2019 Feb 23. doi: 10.1002/ijc.32229. [Epub ahead of print]
Impactfactor: 4,982

Waalboer-Spuij R, **Hollestein LM**, Nijsten TE, **van de Poll-Franse LV**. Satisfaction with Information Provision and Health-related Quality of Life in Basal and Squamous Cell Carcinoma Patients: A Cross-sectional Population-based Study. *Acta Derm Venereol*. 2019 Sep 1;99(10):933-934. doi: 10.2340/00015555-3226.
Impactfactor: 3,531

Wakkee M, van Egmond S, **Louwman MW**, Bindels P, van der Lei J, Nijsten T, Hollestein LM. Opportunities for improving the efficiency of keratinocyte carcinoma care in primary and specialist care: Results from population-based Dutch cohort studies. *Eur J Cancer*. 2019 Aug;117:32-40. doi: 10.1016/j.ejca.2019.05.010. Epub 2019 Jun 21.
Impactfactor: 6,680

Yu WY, Waalboer-Spuij R, Bremer R, Lu B, Aroyan C, Crow L, Grekin R, Neuhaus I, Yu S, Arron ST, **Hollestein LM**. Validation of the English Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) Questionnaire. *Dermatol Surg*. 2019 Aug 6. doi: 10.1097/DSS.0000000000002046. [Epub ahead of print]
Impactfactor: 2,190

8.2 Proefschriften en promoties

Noels EC. Organisation of skin cancer care revisited. Rotterdam: Erasmus Universiteit; 12 november 2019. Promotoren: TE Nijsten, **VE Lemmens**.

Waalboer-Spuij RE. Disease specific quality of life in keratinocyte cancer: the development and use of the BaSQoL questionnaire. Rotterdam: Erasmus Universiteit; 30 oktober 2019. Promotoren: TE Nijsten, **LV van de Poll-Franse**. Co-promotor: **LM Zandwijk-Hollestein**.

9 Longkanker

9.1 Publicaties met impactfactor

Detillon DE, **Aarts MJ**, De Jaeger K, Van Eijck CH, Veen EJ. Video-assisted thoracic lobectomy *versus* stereotactic body radiotherapy for stage I non-small cell lung cancer in elderly patients: a propensity matched comparative analysis. *Eur Respir J*. 2019 Mar 28. pii: 1801561. doi: 10.1183/13993003.01561-2018. [Epub ahead of print]
Impactfactor: 11,807

Driessen EJ, Detillon D, Bootsma G, De Ruyscher D, Veen E, **Aarts MJ**, Janssen-Heijnen M. Population-based patterns of treatment and survival for patients with stage I and II non-small cell lung cancer aged 65-74 years and 75 years or older. *J Geriatr Oncol*. 2019 Mar 12. pii: S1879-4068(18)30429-6. doi: 10.1016/j.jgo.2019.03.001. [Epub ahead of print]
Impactfactor: 3,164

Geerse OP, Brandenburg D, Kerstjens HA, Berendsen AJ, Duijts SFA, Burger H, Holtman GA, **Hoekstra-Weebers JE**, Hiltermann TJ. The distress thermometer as a prognostic tool for one-year survival among patients with lung cancer. *Lung Cancer*. 2019 Apr;130:101-107. doi: 10.1016/j.lungcan.2019.02.008. Epub 2019 Feb 10.
Impactfactor: 4,599

Hermans BC, Derks JL, Thunnissen E, van Suylen RJ, den Bakker MA, Groen HJ, Smit EF, **Damhuis RA**, van den Broek EC; PALGA-group, Ruland A, Speel EJ, Dingemans AM. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile. *Lung Cancer*. 2019 Dec;138:102-108. doi: 10.1016/j.lungcan.2019.10.010. Epub 2019 Oct 13.
Impactfactor: 4,599

Hermans BC, Derks JL, Thunnissen E, van Suylen RJ, den Bakker MA, Groen HJ, Smit EF, **Damhuis RA**, van den Broek EC, Stallinga CM, Roemen GM, Speel EJ, Dingemans AC; PALGA-group. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). *Lung Cancer*. 2019 Apr;130:179-186. doi: 10.1016/j.lungcan.2019.02.022. Epub 2019 Feb 21.
Impactfactor: 4,599

Ten Berge DM, **Aarts MJ**, Hanssens PE, Beute GN, Aerts JG, Kloover JS. Referral Patterns and Outcome of Patients With Synchronous Brain Metastases From Non-small Cell Lung Cancer Treated With Gamma Knife Radiosurgery in a Third-Line Treatment Centre in The Netherlands - A Retrospective Analysis. *Clin Oncol (R Coll Radiol)*. 2019 Jul 22. pii: S0936-6555(19)30284-5. doi: 10.1016/j.clon.2019.07.004. [Epub ahead of print]
Impactfactor: 3,055

9.2 Presentaties en abstracts

Damhuis RA, Senan S, Khakwani A, Harden S, Helland A, Strand TE. Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries. ELCC, European Lung Cancer Congress; 10-13 april 2019; Genève.

Damhuis RA, Senan S, Khakwani A, Harden S, Helland A, Strand TE. Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries. ENETS conference for the diagnosis and treatment of neuroendocrine tumor disease; 6-8 maart; Barcelona.

Hermans B, Derks JL, Thunnissen E, van Suylen RJ, den Bakker MA, Groen HJ, Smit EF, **Damhuis RA**, van den Broek EC, Dingemans AM, Speel EJ. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). ENETS conference for the diagnosis and treatment of neuroendocrine tumor disease; 6-8 maart; Barcelona.

Kuipers C, van den Heuvel M, van Lindert A, **Damhuis RA**, Willems S. Best practice session on lung cancer molecular diagnostics in the Netherlands to enhance testing proportions nationwide. IASLC, World conference on lung cancer; 7-10 september 2019; Barcelona.

Kuipers C, van den Heuvel M, van Lindert A, **Damhuis RA**, Willems S. Evaluation of molecular testing in a Dutch cohort of metastatic non-small cell lung cancer patients from 2017. IASLC, World conference on lung cancer; 7-10 september 2019; Barcelona.

Kuipers C, van den Heuvel M, Overbeek L, van Lindert A, **Damhuis RA**, Willems S. Notable variation of molecular testing in metastatic lung cancer in the Netherlands. ELCC, European Lung Cancer Congress; 10-13 april 2019; Genève.

10 Neuro-endocriene tumoren

10.1 Publicaties met impactfactor

Tas ML, Reedijk AM, [Karim-Kos HE](#), Kremer LC, van de Ven CP, Dierselhuis MP, van Eijkelenburg NK, van Grotel M, Kraal KC, Peek AM, Coebergh JW, Janssens GO, de Keizer B, de Krijger RR, Pieters R, Tytgat GA, van Noesel MM. [Neuroblastoma between 1990 and 2014 in the Netherlands: Increased incidence and improved survival of high-risk neuroblastoma](#). *Eur J Cancer*. 2019 Nov 11;124:47-55. doi: 10.1016/j.ejca.2019.09.025. [Epub ahead of print]
Impactfactor: 6,680

11 Neuro-oncologie

11.1 Publicaties met impactfactor

De Witt Hamer PC, [Ho VK](#), Zwinderman AH, Ackermans L, Ardon H, Boomstra S, Bouwknecht W, van den Brink WA, Dirven CM, van der Gaag NA, van der Veer O, Idema AJ, Kloet A, Koopmans J, Ter Laan M, Versteegen MJ, Wagemakers M, Robe PA; Quality Registry Neuro Surgery glioblastoma working group from the Dutch Society of Neurosurgery. [Between-hospital variation in mortality and survival after glioblastoma surgery in the Dutch Quality Registry for Neuro Surgery](#). J Neurooncol. 2019 Jun 24. doi: 10.1007/s11060-019-03229-5. [Epub ahead of print]
Impactfactor: 3,129

Meulepas JM, Ronckers CM, Smets AM, Nievelstein RA, Gradowska P, Lee C, Jahnen A, van Straten M, de Wit MY, Zonnenberg B, Klein WM, Merks JH, [Visser O](#), van Leeuwen FE, Hauptmann M. [Response to Wollschläger, Blettner, and Pokora](#). J Natl Cancer Inst. 2019 Apr 12. pii: djz062. doi: 10.1093/jnci/djz062. [Epub ahead of print] No abstract available.
Impactfactor: 10,211

12 Upper GI & HPB

12.1 Publicaties met impactfactor

Baranov NS, Nagtegaal ID, van Grieken NC, **Verhoeven RH**, Voorham QJ, Rosman C, van der Post RS. Synoptic reporting increases quality of upper gastrointestinal cancer pathology reports. *Virchows Arch*. 2019 May 29. doi: 10.1007/s00428-019-02586-w. [Epub ahead of print]
Impactfactor: 2,868

de Boer NL, van Kooten JP, **Damhuis RA**, Aerts JG, Verhoef C, Madsen EV. Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study. *Ann Surg Oncol*. 2019 Oct 16. doi: 10.1245/s10434-019-07803-z. [Epub ahead of print]
Impactfactor: 3,681

de Leede N, Bastiaannet E, **van der Geest LG**, Egan K, van de Velde C, Balducci L, Bonsing B, Extermann M. An international comparison of treatment and short-term overall survival for older patients with pancreatic cancer. *J Geriatr Oncol*. 2019 Feb 21. pii: S1879-4068(18)30204-2. doi: 10.1016/j.jgo.2019.02.006. [Epub ahead of print]
Impactfactor: 3,164

de Savornin Lohman EA, **van der Geest LG**, de Bitter TJ, Nagtegaal ID, van Laarhoven CJ, van den Boezem P, van der Post CS, de Reuver PR. Re-resection in Incidental Gallbladder Cancer: Survival and the Incidence of Residual Disease. *Ann Surg Oncol*. 2019 Nov 18. doi: 10.1245/s10434-019-08074-4. [Epub ahead of print]
Impactfactor: 3,681

de Vos-Geelen J, Geurts SM, **van Putten M**, Valkenburg-van Iersel LB, Grabsch HI, Haj Mohammad N, Hoebbers FJ, Hoge CV, Jeene PM, de Jong EJ, van Laarhoven HW, Rozema T, Slingerland M, Tjan-Heijnen VC, Nieuwenhuijzen GA, **Lemmens VE**. Trends in treatment and overall survival among patients with proximal esophageal cancer. *World J Gastroenterol*. 2019 Dec 21;25(47):6835-6846. doi: 10.3748/wjg.v25.i47.6835.
Impactfactor: 3,411

Dijksterhuis WP, **Verhoeven RH**, Slingerland M, Haj Mohammad N, de Vos-Geelen J, Beerepoot LV, van Voorthuizen T, Creemers GJ, **van Oijen MG**, van Laarhoven HW. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: a real-world evidence study. *Int J Cancer*. 2019 Jul 24. doi: 10.1002/ijc.32580. [Epub ahead of print]
Impactfactor: 4,982

Faiz Z, **van Putten M**, **Verhoeven RH**, van Sandick JW, Nieuwenhuijzen GA, van der Sangen MJ, **Lemmens VE**, Wijnhoven BP, Plukker JT. Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment Options for Patients with Potentially Curable Esophageal Cancer. *Ann Surg Oncol*. 2019 Feb 4. doi: 10.1245/s10434-019-07181-6. [Epub ahead of print]
Impactfactor: 3,681

Huang L, Balavarca Y, **van der Geest LG**, **Lemmens VE**, Van Eycken L, De Schutter H, Johannesen TB, Zadnik V, Primic-Zakelj M, Mägi M, Grützmänn R, Besselink MG, Schrotz-King P, Brenner H, Jansen L. Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study. *BMC Med*. 2019 Mar 25;17(1):66. doi: 10.1186/s12916-019-1304-y.
Impactfactor: 8,285

Huang L, Jansen L, Balavarca Y, **van der Geest LG**, **Lemmens VE**, Groot Koerkamp B, van Santvoort HC, Grützmänn R, Besselink MG, Schrotz-King P, Brenner H. Significance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage I-II Pancreatic Cancer-More is Better? A Large International Population-based Cohort Study. *Ann Surg*. 2019 Aug 13. doi: 10.1097/SLA.0000000000003558. [Epub ahead of print]
Impactfactor: 9,476

Latenstein AE, **van der Geest LG**, Bonsing BA, Groot Koerkamp B, Haj Mohammad N, de Hingh IH, de Meijer VE, Molenaar IQ, van Santvoort HC, van Tienhoven G, Verheij J, **Vissers PA**, de Vos-Geelen J, Busch OR, van Eijck CH, van Laarhoven HW, Besselink MG, Wilmink JW; Dutch Pancreatic Cancer Group. *Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma*. Eur J Cancer. 2019 Dec 13;125:83-93. doi: 10.1016/j.ejca.2019.11.002. [Epub ahead of print]
Impactfactor: 6,680

Mokadem I, Dijksterhuis WP, **van Putten M**, Heuthorst L, de Vos-Geelen JM, Haj Mohammad N, Nieuwenhuijzen GA, van Laarhoven HW, **Verhoeven RH**. *Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study*. Gastric Cancer. 2019 Apr 4. doi: 10.1007/s10120-019-00956-6. [Epub ahead of print]
Impactfactor: 5,554

Stroes CI, Schokker S, Creemers A, Molenaar RJ, Hulshof MC, van der Woude SO, Bennink RJ, Mathôt RA, Krishnadath KK, Punt CJ, **Verhoeven RH**, van Oijen MG, Creemers GJ, Nieuwenhuijzen GA, van der Sangen MJ, Beerepoot LV, Heisterkamp J, Los M, Slingerland M, Cats A, Hospers GA, Bijlsma MF, van Berge Henegouwen MI, Meijer SL, van Laarhoven HW. *Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study*. J Clin Oncol. 2019 Dec 6;JCO1901814. doi: 10.1200/JCO.19.01814. [Epub ahead of print]
Impactfactor: 28,349

Strijker M, Belkouz A, **van der Geest LG**, van Gulik TM, van Hooft JE, de Meijer VE, Haj Mohammad N, de Reuver PR, Verheij J, de Vos-Geelen J, Wilmink JW, Groot Koerkamp B, Klümpen HJ, Besselink MG; Dutch Pancreatic Cancer Group. *Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study*. Acta Oncol. 2019 Mar 25:1-8. doi: 10.1080/0284186X.2019.1590634. [Epub ahead of print]
Impactfactor: 3,298

van den Boorn HG, Abu-Hanna A, Ter Veer E, van Kleef JJ, Lordick F, Stahl M, Ajani JA, Guimbaud R, Park SH, Dutton SJ, Bang YJ, Boku N, Mohammad NH, Sprangers MA, **Verhoeven RH**, Zwinderman AH, van Oijen MG, van Laarhoven HW. *SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer*. Cancers (Basel). 2019 Feb 5;11(2). pii: E187. doi: 10.3390/cancers11020187.
Impactfactor: 6,162

van der Werf LR, Eshuis WJ, Draaisma WA, van Etten B, Gisbertz SS, van der Harst E, Liem MS, **Lemmens VE**, Wijnhoven BP, Besselink MG, van Berge Henegouwen MI; Dutch Upper Gastrointestinal Cancer Audit (DUCA) group. *Nationwide Outcome of Gastrectomy with En-Bloc Partial Pancreatectomy for Gastric Cancer*. J Gastrointest Surg. 2019 Feb 28. doi: 10.1007/s11605-019-04133-z. [Epub ahead of print]
Impactfactor: 2,686

van Hilst J, Strating EA, de Rooij T, Daams F, Festen S, Groot Koerkamp B, Klaase JM, Luyer M, Dijkgraaf MG, Besselink MG; Dutch Pancreatic Cancer Group and LEOPARD trial collaborators (**de Hingh IH**). *Costs and quality of life in a randomized trial comparing minimally invasive and open distal pancreatectomy (LEOPARD trial)*. Br J Surg. 2019 Jun;106(7):910-921. doi: 10.1002/bjs.11147.
Impactfactor: 5,572

van Hilst J, de Rooij T, Bosscha K, Brinkman DJ, van Dieren S, Dijkgraaf MG, Gerhards MF, **de Hingh IH**, Karsten TM, Lips DJ, Luyer MD, Busch OR, Festen S, Besselink MG; Dutch Pancreatic Cancer Group. *Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial*. Lancet Gastroenterol Hepatol. 2019 Jan 23. pii: S2468-1253(19)30004-4. doi: 10.1016/S2468-1253(19)30004-4. [Epub ahead of print]
Impactfactor: 12,856

van Kleef JJ, Ter Veer E, van den Boorn HG, Schokker S, Ngai LL, Prins MJ, Mohammad NH, **van de Poll-Franse LV**, Zwinderman AH, van Oijen MG, Sprangers MA, van Laarhoven HW. *Quality of life during palliative systemic therapy for oesophagogastric cancer: systematic review and meta-analysis*. J Natl Cancer Inst. 2019 Jun 28. pii: djz133. doi: 10.1093/jnci/djz133. [Epub ahead of print]
Impactfactor: 10,211

van Putten M, Lemmens VE, van Laarhoven HW, Pruijt HF, Nieuwenhuijzen GA, **Verhoeven RH**. Poor compliance with perioperative chemotherapy for resectable gastric cancer and its impact on survival. *Eur J Surg Oncol*. 2019 Apr 6. pii: S0748-7983(19)30385-3. doi: 10.1016/j.ejso.2019.03.040. [Epub ahead of print]
Impactfactor: 3,379

12.2 Overige publicaties

Claassen YH, Bastiaannet E, Hartgrink HH, Dikken JL, de Steur WO, Slingerland M, **Verhoeven RH**, van Eycken E, de Schutter H, Lindblad M, Hedberg J, Johnson E, Hjortland GO, Jensen LS, Larsson HJ, Koessler T, Chevally M, Allum WH, van de Velde CJ. *International comparison of treatment strategy and survival in metastatic gastric cancer*. *BJs Open*. 2018 Oct 9;3(1):56-61. doi: 10.1002/bjs5.103. eCollection 2019 Feb.

12.3 Proefschriften en promoties

Bakens MJ. Variation in pancreatic cancer care in the Netherlands. Maastricht: Universiteit Maastricht; 18 april 2019. Promotores: IH de Hingh, CH Dejong, **VE Lemmens**.

van der Geest LG. Quality of care for pancreatic cancer patients, with focus on the elderly. Amsterdam: Universiteit van Amsterdam; 15 februari 2019. Promotores: OR Busch, **VE Lemmens**.

12.4 Posters

Luijten JC, Verstegen M, van Workum F, Nieuwenhuijzen GA, van Berge Henegouwen MI, Gisbertz SS, van Wijnhoven BP, **Verhoeven RH**, Rosman C. Long-term outcomes of Ivor Lewis versus McKeown oesophagectomy for cancer: a propensity score matched analysis of the Netherlands Cancer Registry. ESSO, The European Society of Surgical Oncology Congres; 9-11 oktober 2019; Rotterdam.

Luijten JC, Vissers PA, Lingsma H, van Leeuwen N, Rozema T, Siersema PD, Rosman C, van Laarhoven HW, **Lemmens VE**, Nieuwenhuijzen GA, **Verhoeven RH**. Variation in the probability of receiving treatment with curative intent for oesophageal and gastric cancer according to hospital of diagnosis in the Netherlands. ESSO, The European Society of Surgical Oncology Congres; 9-11 oktober 2019; Rotterdam.

12.5 Presentaties en abstracts

Corten B, de Savornin Lohman E, Leclercq W, Roumen R, **Verhoeven RH**, van Zwam P, de Reuver P, Dejong C, Slooter G. Is selective histopathologic examination of the gallbladder permissible? ESSO, The European Society of Surgical Oncology Congres; 9-11 oktober 2019; Rotterdam.

Dijksterhuis WP, Verhoeven RH, Meijer SL, Slingerland M, Haj Mohammed N, de Vos-Geelen J, Beerepoot LV, van Voorthuizen T, Creemers GJ, **van Oijen M**, van Laarhoven HW. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study. ESMO, World Congress on Gastrointestinal Cancer; 27 september-1 oktober 2019; Barcelona.

Groen J, Douwes T, van Eyken L, **van der Geest LG**, Johannesen T, Bonsing B, van der Velde C, Bastiaannet E, Mieog S. Older patients with pancreatic cancer stage I-II in Belgium, Norway and the Netherlands from the EURECCA Pancreas Consortium. ESSO, The European Society of Surgical Oncology Congres; 9-11 oktober 2019; Rotterdam.

Koemans W, **Luijten JC**, van der Kraaij RT, Grootcholten C, Snaebjornsson P, **Verhoeven RH**, van Sandick JW. The metastatic pattern of intestinal and diffuse type gastric adenocarcinoma: a Dutch national cohort study. ESSO, The European Society of Surgical Oncology Congres; 9-11 oktober 2019; Rotterdam.

Luijten JC, Verstegen M, Nieuwenhuijzen G, van Berge Henegouwen M, Gisbertz S, van Wijnhoven B, **Verhoeven RH**, Rosman C. Outcomes of Ivor Lewis Mckeown oesophagectomy for cancer: a propensity score matched analysis of the Netherlands Cancer Registry. ESSO, The European Society of Surgical Oncology Congres; 9-11 oktober 2019; Rotterdam.

van der Geest LG, Lemmens VE, de Hingh I, van Laarhoven K, Bollen T, Nio Y, van Eijck C, Busch O, Besselink M. Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. E-AHPBA, European-African hepato-pancreato-biliary association; 2-5 juni 2019; Amsterdam.

13 Urogenitale kanker

13.1 Publicaties met impactfactor

Cuypers M, Al-Itejawi HH, van Uden-Kraan CF, Stalmeier PF, Lamers RE, van Oort IM, Somford DM, van Moorselaar RJ, Verdonck-de Leeuw IM, [van de Poll-Franse LV](#), van Tol-Geerdink JJ, de Vries M. Introducing Decision Aids into Routine Prostate Cancer Care in The Netherlands: Implementation and Patient Evaluations from the Multi-regional JIPPA Initiative. *J Cancer Educ*. 2019 Jul 5. doi: 10.1007/s13187-019-01572-9. [Epub ahead of print]
Impactfactor: 1,690

de Goeij L, Westhoff E, Witjes JA, [Aben KK](#), Kampman E, Kiemeney LA, Vrieling A. The UroLife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life. *BMJ Open*. 2019 Oct 16;9(10):e030396. doi: 10.1136/bmjopen-2019-030396.
Impactfactor: 2,376

Donnelly DW, Vis LC, Kearney T, Sharp L, Bennett D, Wilding S, Downing A, Wright P, Watson E, Wagland R, Cross WR, Mason MD, [Siesling S](#), van Manen JG, Glaser AW, Gavin A. Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes study. *BMC Cancer*. 2019 Oct 15;19(1):947. doi: 10.1186/s12885-019-6164-5.
Impactfactor: 2,933

Liem EI, Oddens JR, [Vernooij RW](#), Li R, Kamat AM, Dinney CP, Mengual L, Alcaraz A, Izquierdo L, Savic S, Thalmann GN, Bubendorf L, Sylvester RJ, de Reijke TM. The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guérin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Data. *J Urol*. 2019 Sep 24;101097 JU0000000000000566. doi: 10.1097/JU.0000000000000566. [Epub ahead of print]
Impactfactor: 5,647

[Richters A](#), Dickman PW, Witjes JA, Boormans JL, Kiemeney LA, [Aben KK](#). Bladder cancer survival: Women only fare worse in the first two years after diagnosis. *Urol Oncol*. 2019 Aug 31. pii: S1078-1439(19)30319-9. doi: 10.1016/j.urolonc.2019.08.001. [Epub ahead of print]
Impactfactor: 2,863

[Richters A](#), [Aben KK](#), Kiemeney LA. The global burden of urinary bladder cancer: an update. *World J Urol*. 2019 Nov 1. doi: 10.1007/s00345-019-02984-4. [Epub ahead of print] Review.
Impactfactor: 2,761

Tran MG, [Aben KK](#), Werkhoven E, Neves JB, Fowler S, Sullivan M, Stewart GD, Challacombe B, Mahrour A, Patki P, Mumtaz F, Barod R, Bex A; British Association of Urological Surgeons. Guideline adherence for the surgical treatment of T1 renal tumours correlates with hospital volume: an analysis from the British Association of Urological Surgeons Nephrectomy Audit. *BJU Int*. 2019 Jul 11. doi: 10.1111/bju.14862. [Epub ahead of print]
Impactfactor: 4,524

Vrieling A, Bueno-de-Mesquita HB, Ros MM, Kampman E, [Aben KK](#), Büchner FL, Jansen EH, Roswall N, Tjønneland A, Boutron-Ruault MC, Cadeau C, Chang-Claude J, Kaaks R, Weikert S, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Sieri S, Palli D, Panico S, Peeters PH, Weiderpass E, Skeie G, Jakszyn P, Chirlaque MD, Ardanaz E, Sánchez MJ, Ehrnström R, Malm J, Ljungberg B, Khaw KT, Wareham NJ, Brennan P, Johansson M, Riboli E, Kiemeney LA. One-carbon metabolism biomarkers and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer*. 2019 Jan 29. doi: 10.1002/ijc.32165. [Epub ahead of print]
Impactfactor: 4,982

Vromans RD, van Eenbergen MC, Pauws SC, Geleijnse G, van der Poel HG, van de Poll-Franse LV, Krahmer EJ. Communicative aspects of decision aids for localized prostate cancer treatment - A systematic review. *Urol Oncol*. 2019 Apr 30. pii: S1078-1439(19)30138-3. doi: 10.1016/j.urolonc.2019.04.005. [Epub ahead of print] Review. Impactfactor: 2,863

Westhoff E, Kampman E, Aben KK, Hendriks IG, Witjes JA, Kiemeny LA, Vrieling A. Low awareness, adherence, and practice but positive attitudes regarding lifestyle recommendations among non-muscle-invasive bladder cancer patients. *Urol Oncol*. 2019 May 8. pii: S1078-1439(19)30149-8. doi: 10.1016/j.urolonc.2019.04.016. [Epub ahead of print] Impactfactor: 2,863

Wollersheim BM, Boekhout AH, van der Poel HG, van de Poll-Franse LV, Schoormans D. The risk of developing cardiovascular disease is increased for prostate cancer patients who are pharmaceutically treated for depression. *BJU Int*. 2019 Nov 26. doi: 10.1111/bju.14961. [Epub ahead of print] Impactfactor: 4,524

13.2 Overige publicaties

de Vries AW, Klijn FA, Vernooij RW, Aben KK, de Reijke TM. Prostaatankerrichtlijn: een routekaart in Oncoguide, beslisbomen en informatiestandaard. *Tijdschr Urol*. 2019 Feb. doi.org/10.1007/s13629-019-0250-y.

Rijksen BL, Pos FJ, Hulshof MC, Vernooij RW, Jansen H, van Andel G, Wijsman BP, Somford DM, Busstra MB, van Moorselaar RJ, Kaa CA, van Leenders GJ, Hamberg P, van den Berkmortel F, Fütterer JJ, Kiemeny LA, van Oort IM, Aben KK. Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study. *Eur Urol Focus*. 2019 Nov 17. pii: S2405-4569(19)30346-3. doi: 10.1016/j.euf.2019.11.005. [Epub ahead of print]

van der Poel H, van der Kwast T, Aben KK, Mottet N, Mason M. Imaging and T Category for Prostate Cancer in the 8th Edition of the Union for International Cancer Control TNM Classification. *Eur Urol Oncol*. 2019 Jul 12. pii: S2588-9311(19)30076-8. doi: 10.1016/j.euo.2019.06.001. [Epub ahead of print] No abstract available.

13.3 Proefschriften en promoties

Boer H. Survivorship care after testicular cancer: new insights in late effects of treatment and approaches to shared-care follow-up. Groningen: Rijksuniversiteit Groningen; 25 februari 2019. Promotors: JA Gietema, S Siesling.

Lamers RE. Treatment decision making in patients with prostatic disorders. Utrecht: UMC; 21 november 2019. Promotoren: JL Bosch, LV van de Poll-Franse.

13.4 Presentaties en abstracts

Richters A, Dickman PW, Witjes JA, Kiemeny LA, Aben KK. Survival differences between men and women with bladder cancer depend strongly on time since diagnosis. EAU, European Association of Urology Conference; 15-19 maart 2019; Barcelona.

Vromans R, van Eenbergen ME, Pauws S, Geleijnse G, van der Poel H, van de Poll-Franse LV, Krahmer E. Assessing communicative aspects of patient decision aids for localized prostate cancer treatment: a systematic review. ICT.Open Conferentie; 19-20 maart 2019; Hilversum.

Vromans R, van Eenbergen ME, Pauws S, Geleijnse G, van der Poel H, van de Poll-Franse LV, Krahmer E. Communicative aspects of decision aids for prostate cancer treatment: state of affairs, limitations, and recommendations. International Communication Association Annual Conference; 24-28 mei 2019; Washington.

B1 Impactfactoren tijdschriften

Van de 205 peer-reviewed artikelen werd 94% gepubliceerd in een tijdschrift met een impactfactor. De maximale impactfactor bedroeg 35,386 en de gemiddelde impactfactor was 5,2. (de impactfactor is gebaseerd op 2018 Journal Citation Reports®).

Tabel 1 Overzicht tijdschriften met impactfactor

<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
Acta Oncologica	3,298	7
Acta Dermato-Venereologica	3,531	2
American Journal of Physical medicine & rehabilitation	1,908	1
Annals of Internal Medicine	19,315	6
Annals of Oncology	14,196	1
Annals of Surgery	9,476	1
Annals of Surgical Oncology	3,681	9
Archives of Gynecology and Obstetrics	2,199	1
BJD British Journal of Dermatology	6,714	2
BJH British Journal of Haematology	5,206	1
BJS British Journal of Surgery	5,572	3
BJU International	4,524	2
BMC Cancer	2,933	4
BMC Medical Research Methodology	2,509	2
BMC Medicine	8,285	1
BMJ Open	2,376	4
BMJ Supportive & Palliative Care	3,208	1
Breast Cancer Research	5,676	2
Breast Cancer Research and Treatment	3,471	8
Cancer	6,102	1
Cancer Causes & Control	2,3	1
Cancer Control	1,990	1
Cancer Epidemiology	2,619	1
Cancer Medicine	3,357	1
Cancers (Basel)	6,162	4
Clinical Cancer Research	8,911	1
Clinical Colorectal Cancer	3,176	1
Clinical Oncology Journal	3,055	1
Clinical Otolaryngology	2,377	1
Current Oncology	1,862	1
Dermatologic Surgery	2,190	1
Dermatology	2,497	2
Diabetes Care	15,270	1
Digestive Surgery	1,884	1
EJC European Journal of Cancer	6,680	11
EJOG European Journal of Obstetrics & Gynecology and Rep.Biol.	2,024	1
EJSO European Journal of Surgical Oncology	3,379	11
European Journal of Cancer Care	2,421	1
European Respiratory Journal	11,807	1

<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
Frontiers in Oncology	4,137	1
Gastric Cancer	5,554	1
Gynecologic Oncology	4,393	4
Haematologica	7,570	1
Head & Neck	2,442	1
Histopathology	3,294	2
IBD Inflammatory Bowel Diseases	4,005	1
IJC International Journal of Cancer	4,982	10
International Journal of Gynecological cancer	1,746	2
JAAD Journal of the American Academy of Dermatology	7,102	1
JAMA Oncology	22,416	1
JCE Journal of Clinical Epidemiology	4,650	1
JNCI Journal of the National Cancer Institute	10,211	3
Journal of Cancer Education	1,690	1
Journal of Cancer Research and Clinical Oncology	3,332	2
Journal of Cancer Survivorship	3,585	4
Journal of Clinical Oncology	28,349	1
Journal of Gastrointestinal Surgery	2,686	1
Journal of Geriatric Oncology	3,164	4
Journal of Neuro-oncology	3,129	1
Journal of Palliative Medicine	2,477	1
Journal of Psychosocial Oncology	1,197	1
Journal of Psychosomatic Research	2,722	1
Journal of Surgical Oncology	3,114	1
Journal of the European Academy of Dermatology and Ven.	5,113	1
Journal of Urology	5,647	3
JPSM Journal of Pain and Symptom Management	3,378	1
Lung Cancer	4,599	3
Mayo Clinic Proceedings Innovations, Quality & Outcomes	7,091	1
Medicine & Science in Sports & Exercise	4,478	1
Obesity Surgery	3,603	1
Plastic and Reconstructive Surgery	3,946	1
PloS One	2,776	2
Psycho-Oncology	3,43	1
Public Health Genomics	1,527	1
Quality of Life Research	2,488	1
Radiotherapy & Oncology	5,252	1
SCI Stem Cell Investigation	4,806	1
Supportive Care in Cancer	2,754	5
Targeted Oncology	3,683	1
The Breast	3,494	2
The Breast Journal	2,433	1
The Lancet Gastroenterology & Hepatology	12,856	2
The Lancet Oncology	35,386	1
The Oncologist	5,252	3
United European Gastroenterology Journal	3,453	1
Urologic Oncology: Seminars and Original Investigations	2,863	3

<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
Urology	1,861	1
Virchows Archiv	2,868	2
WJG World Journal of Gastroenterology	3,411	1
World Journal of Surgery	2,768	1
World Journal of Urology	2,761	1

Tabel 2 **Overzicht tijdschriften zonder impactfactor**

Asia-Pacific Journal of Oncology Nursing	1
BJS Open	1
European Urology Focus	1
European Urology Oncology	1
JCO Clinical Care Informatics	3
JMIR Cancer	1
NtvG Nederlands Tijdschrift voor Geneeskunde	3
Tijdschrift voor Urologie	1

Integraal Kankercentrum
Nederland
info@iknl.nl
www.iknl.nl

